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Immunomodulatory pathways and metabolism 
 
ABSTRACT 
 
 Energy metabolism plays a vital role in normal physiology, adaptive responses and host 
defense mechanisms. Research throughout the last decade has shown evidence that immune 
pathways communicate with metabolic pathways to alter the metabolic status in response to 
physiological or pathological signals. In this thesis, I will explore how immunomodulatory 
molecules affect metabolic homeostasis and conversely, how metabolic sensing pathways 
modulate immune responses. The first part my work utilizes an immunomodulatory sugar motif 
to determine mechanisms by which immune cells influence metabolism. Specifically, I show in 
chapter 2 that lacto-N-fucopentaose III (LNFPIII), a motif used by pathogens to attenuate 
inflammation, is capable of improving systemic insulin sensitivity by increasing Il-10 production 
in macrophages and dendritic cells and subsequently improving white adipose tissue insulin 
sensitivity. Chapter 3 will address the observation that this same glycan is capable of directly 
activating Fxrα in hepatocytes. This direct effect manifests as a reduction in high-fat-diet-
induced hepatic triglyceride accumulation and improvement in liver function. Lastly, in chapter 
4, I will discuss the role of metabolic regulators in the macrophage and how this affects the 
ability of the macrophage to kill bacteria. Specifically, I will show that lipid sensing nuclear 
receptors, such as Pparδ and Pparγ, are critical regulators of phagosomal function and bacterial 
killing. Macrophage-specific deletion of these receptors prevents efficient killing of 
Streptococcus pneumoniae, the causative bacterium in many cases of respiratory pneumonia. 
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Ligand activation improves survival, suggesting a potential therapeutic role for Ppar activation 
during infection. Taken together, all the data suggest a critical role for the evolutionary 
interaction between metabolic and immune pathways. These interactions may be important when 
developing new therapeutics for complex metabolic and immunological dysfunctions.  
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Chapter 1 
INTRODUCTION 
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The innate immune system, which consists of macrophages, dendritic cells, and a variety 
of other effector cells, has evolved as a formidable defense against external threats to the human 
host. When first described by Elie Metchnikoff in the late 1800s, macrophages were thought to 
primarily function as phagocytes. In the next several decades, intense effort went into 
understanding the mechanisms that led to macrophage activation. It was not until about 100 
years later that researchers first started to document the innumerable roles that macrophages 
play1. We now know that macrophages are found throughout the body and are involved in tissue 
homeostasis, wound healing, general surveillance of host threats, and as was first observed, 
killing of foreign pathogens.  
Abundant sources of food that have high energy content and are enriched in saturated 
fats, coupled with a lack of physical activity, are responsible for the sharp increase in a collection 
of pathologies, such as obesity, hepatosteatosis, insulin resistance and atherosclerosis, together 
known as the metabolic syndrome. All these pathologies increase the chance of developing 
cardiovascular disease, diabetes mellitus, and premature death2.  
The observation that anti-inflammatory salicylates could improve insulin sensitivity and 
glucose responsiveness gave the first indication that metabolic syndrome is associated with low-
grade chronic inflammation3,4. This was followed by reports that inflammatory cytokines, such 
as tumor necrosis factor α (Tnfα), inhibit insulin responsiveness in adipocytes, providing a link 
between inflammation and metabolic pathways5-7. Subsequent studies have suggested that lipid 
overload triggers the immune system, especially macrophages, to respond in a deleterious 
manner, in which a resolution state could not be achieved8,9. At around the same time when these 
studies were occurring, researchers observed that insulin resistance and hyperglycemia lead to 
dysregulated immune responses and increased incidences of infection in patients with the 
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metabolic syndrome10-17. Together, it has become evident that metabolic pathways are tightly 
intertwined with inflammatory signaling and immune responses and play an integral role in their 
respective functions.  
As environmental sentries, it is not surprising that macrophages sense and regulate 
metabolic homeostasis. This link between macrophages and metabolic regulation was further 
strengthened with the discovery of resident macrophage populations in metabolically active 
tissues, such as white adipose tissue and liver18,19. The interplay between resident macrophages 
and pathologies associated with the metabolic syndrome has been studied extensively since.  
 
AN ESSENTIAL ROLE FOR MACROPHAGES IN METABOLIC PATHOLOGIES 
 Resident macrophages in different tissues adapt to their local microenvironment and 
exhibit diverse functional and morphological phenotypes. Resident populations, such as Kupffer 
cells in the liver, resident macrophages in white adipose tissue (WAT) and alveolar macrophages 
in the lung, show expression profiles distinct from those of recruited macrophages responding to 
systemic cues1. For example, studies have demonstrated that adipose tissue resident macrophages 
(ATMs) are functionally distinct from infiltrating macrophages (discussed below). In the process 
of understanding the etiology of metabolic syndrome, we have begun to understand the general 
mechanisms underlying metabolic diseases, particularly the roles of macrophages in 
atherosclerosis and in adipose tissue insulin resistance. Due to lack of specific markers for 
resident and recruited macrophages and the crosstalk between tissues in the progression of 
metabolic diseases, it is often difficult to tease apart the precise contribution of individual 
macrophage populations to the onset and development of systemic metabolic dysfunction. 
Nonetheless, it is clear that the interaction between macrophages and metabolic cells plays a key 
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role in disease pathogenesis. Macrophages are recruited by proinflammatory cytokines and 
chemokines to deal with lipid overload-induced tissue dysfunction and are also subject to the 
detrimental effects of lipid influx. As such, metabolic stress initiates a feed-forward cycle of 
inflammatory responses resulting in a state of unresolved, chronic inflammation with 
macrophages as major culprits contributing to metabolic diseases (Fig 1). 
 
Macrophage infiltration and activation  
Recruitment: The production of chemokines, the factors that recruit immune cells to sites of 
trouble, is increased in states of metabolic dysfunction. Monocyte chemoattractant protein 1 
[Mcp1, also known as chemokine (C-C motif) ligand 2 (Ccl2)] and its receptor Ccr2 are the most 
studied chemokine signaling molecules in metabolic diseases. Earlier studies have demonstrated 
that Mcp1 and Ccr2 gene knockout mice are protected from atherosclerosis20-22. Ccr2 knockout 
mice also display attenuated macrophage accumulation and chronic inflammation in adipose 
tissue23. In addition, mice lacking Mcp1 or expressing a dominant negative form of Mcp1 show 
improved insulin sensitivity24, whereas transgenic Mcp1 overexpression in adipose tissue causes 
insulin resistance and hepatic steatosis24,25. Other chemokines, such as osteopontin, angiopoietin-
like protein 2, and chemokine (C-X-C motif) ligand 14 (Cxcl14) have also been shown to play a 
role in obesity induced macrophage recruitment26-29. These studies demonstrate that macrophage 
infiltration is an essential step for metabolic disease pathogenesis. 
 
Activation: Macrophages respond to many different types of foreign and host derived stimuli and 
exhibit very precise and coordinated activation states based on the signals they receive. These 
states lie on a spectrum ranging from the pro-inflammatory state to the anti-inflammatory state 
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Figure 1:  Metabolic dysregulation leads to a feed-forward cycle of chronic inflammation. Activation of 
inflammatory pathways by metabolic stress leads to macrophage recruitment to sites of affected tissues, such as 
vasculature, white adipose tissue, muscle and liver. There, they accumulate excess lipids and cell debris in an 
attempt to restore homeostasis. The presence of persistent pro-inflammatory stimulants (e.g., fatty acids and 
cholesterol) causes macrophage dysfunction, including defective efferocytosis and unresolved inflammation, 
resulting in recruitment and activation of more macrophages. In white adipose tissue, infiltrated macrophages are 
concentrated around the dying fat cells, known as the crown-like structure. In vasculature, macrophages are enriched 
in areas of fatty streaks. Inflammatory cytokines produced by activated macrophages induce insulin resistance in 
major metabolic tissues, promote hepatosteatosis and facilitate foam cell and plaque formation in the vessel wall.  
 
 
6 
(Fig.2)30. Foreign pathogens or TH1 cytokines [e.g., Tnfα, interleukin 1β (Il-1β) and interferon γ 
(Ifnγ)] transduce signals that activate macrophages to a pro-inflammatory phenotype, typically 
referred to as an M1 response, characterized by the expression of inflammatory markers, such as 
Tnfα, Ifnγ and nitric oxide synthase 2 (Nos2, also known as iNOS)30. In contrast, M2 
macrophages, induced by TH2 cytokines Il-4 and Il-13, produce anti-inflammatory mediators, 
notably Il-1030. As will be discussed below, the M1/M2 paradigm also applies to metabolic 
regulation, with M1 inducing and M2 preventing metabolic diseases, respectively (Fig. 3). 
Interestingly, dietary fatty acids are able to polarize macrophages toward M1 or M2 activation 
states, depending on the signaling molecules with which they interact (Fig. 2), thus providing a 
molecular basis for the crosstalk between metabolic and inflammatory pathways.  
Resolution/deactivation: The initial pro-inflammatory response is terminated by anti-
inflammatory cytokines, such as Il-10, which is induced by both M1 and M2 cytokines to 
deactivate macrophages and promote resolution31-34. Lack of this termination signal leads to 
establishment of the inflammatory response35-37. Epidemiological studies have shown that 
polymorphisms in the IL-10 gene are associated with obesity and metabolic diseases38-40. 
Furthermore, in patients with type 2 diabetes, circulating monocytes express decreased levels of 
IL-1041. Il-10 and other deactivating signaling molecules are also induced during efferocytosis, a 
process by which macrophages engulf and clear apoptotic cells in an effort to prevent necrosis 
and suppress inflammation42. This process is thought to help remove oxidized lipids and 
cholesterol and to activate Akt and Nf-κb survival pathways43. Several studies have shown that 
efficient efferocytosis is necessary to inhibit necrotic plaque formation and defects in 
efferocytosis lead to the formation of unstable lesions and an increase in systemic 
inflammation44-47. Faulty efferocytosis has also been observed in diabetic mouse models and is 
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Figure 2: Dietary lipids and inflammatory mediators share common signaling pathways in the control of 
macrophage activation.  The TH2 (M2) type response, elicited by TH2 cytokines, notably Il-4 and Il-13, and parasitic 
worm infection, induces an anti-inflammatory phenotype in the macrophage and promotes metabolic homeostasis, 
tissue repair, wound healing and angiogenesis. Stat6 is activated by TH2 cytokines to control the expression of Pparδ 
and Pparγ. Together, they regulate mitochondrial oxidative metabolism and macrophage alternative activation. ω3-
Fatty acids DHA and EPA are known to ligate the G protein coupled receptor Gpr120 to promote anti-inflammatory 
responses. These fatty acids can also mediate Ppar activation. In contrast, saturated fatty acids, ceramides 
(metabolites of fatty acids) and cholesterol crystals can induce pro-inflammatory activation of the macrophage 
through pathogen-sensing proteins Tlr2/4, which activate the c-Jun N terminal kinase (Jnk) cascade leading to Nf-κb 
relocation to the nucleus and induction of inflammatory cytokines and glycolytic pathways. Excess lipids have also 
been shown to induce ER stress and inflammasome activation. Pro-inflammatory cytokines produced by these 
macrophages, including Tnfα and Il-1β, cause tissue damage and inhibit insulin signaling, which contribute to the 
pathogenesis of metabolic diseases. 
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Figure 3: Crosstalk between macrophages and adipocytes plays an important role in adipose tissue homeostasis. In 
the physiologic state, adipose tissue resident macrophages exhibit an M2 phenotype, mediated by TH2 cytokines, Il-4 
and Il-13, and downstream transcription factors, Stat6 and Pparδ/Pparγ. Several cell types within white adipose 
tissue have been reported to be sources of TH2 cytokines, including T lymphocytes, eosinophils and adipocytes. ω3-
Fatty acids are also able to induce an anti-inflammatory response through Gpr120 and possibly PPARs. Il-10 is one 
of the well-characterized anti-inflammatory cytokines produced by these macrophages. In obesity, stressed 
adipocytes produce inflammatory mediators (e.g., Mcp-1, Tnfα and saturated fatty acids) to induce M1 activation 
through inflammatory transcription factors, such as Nf-κb. Macrophages respond by up-regulating inflammatory 
cytokines, which activate Jnk and inhibit insulin signaling pathways in the adipocyte.  
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thought to promote inflammatory signaling48. Oxidative stress and macrophage insulin resistance 
are two of the potential mechanisms that cause defective efferocytosis42,49. Therefore, the 
combined effects of persistent pro-inflammatory stimulation from increased lipid influx, 
decreased deactivating signals and compromised efferocytosis lead to the unresolved 
inflammation in metabolic dysregulation.  
 
Macrophages and metabolic pathologies 
Macrophage infiltration and adipose tissue insulin resistance: The stromal vascular fraction 
(SVF) of white adipose tissue (WAT) has been extensively studied in the progression of obesity-
induced insulin resistance. Adipose tissues from lean animals and humans contain a resident 
macrophage population exhibiting the M2 phenotype50 (Fig. 3). In contrast, the obese state is 
characterized by infiltration of M1 macrophages that accumulate around apoptotic fat cells 
(referred to as crown-like structures) and express the Cd11c marker50. It has been suggested that 
macrophages are recruited in response to adipocyte hypertrophy or to signals from dying 
adipocytes in an attempt to restore homeostasis51-53. There, they can be further activated by free 
fatty acids released by dysfunctional fat cells (discussed below), thus amplifying the 
inflammatory response. These macrophages contain lipid droplets derived from direct lipid 
intake or ingestion of dead fat cells and account for up to 40% of the SVF in severe cases of 
obesity23. They secrete pro-inflammatory factors, such as Mcp1, Tnfα and Il-6, which both 
amplify inflammatory responses and inhibit adipocyte insulin signaling18,19. Similarly, 
monocytes from type 2 diabetic patients or obese individuals express more M1 markers41. 
Conditional depletion of Cd11c-expressing macrophages or inhibition of macrophage 
recruitment (e.g., Mcp1 knockout) in obese mice resulted in a significant reduction in systemic 
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inflammation and an improvement in insulin sensitivity24,25,54. It should also be noted that 
adipocytes also produce inflammatory mediators; due to similarities between adipocytes and 
macrophages, the source of pro-inflammatory cytokines/chemokines within WAT is not clear. In 
contrast to WAT, the role of macrophages in brown adipose tissue (BAT) is unclear. A recent 
study suggested that alternatively activated macrophages in WAT produce catecholamines that 
signal to the BAT and promote cold-induced thermogenic responses55. However, a direct role for 
macrophage infiltration into brown adipose tissue (BAT) seems to be limited56,57.  
 
Vascular inflammation and atherosclerosis: The best-characterized macrophage population in 
metabolic syndrome is that of recruited macrophages to sites of endothelial dysfunction in 
atherosclerosis58,59. Elevated low-density lipoprotein cholesterol (LDL-c) levels result in 
accumulation of LDL particles in the sub-endothelial matrix. Careful analyses of temporal 
changes leading to lesion formation revealed that this lipid deposition is the crucial initiating 
event in macrophage recruitment59; the accumulated LDL becomes oxidized (ox-LDL) and 
locally produced cytokines and chemokines, in response to ox-LDL, recruit 
monocytes/macrophages into the sub-endothelial space. Lipid particles are taken up by 
macrophages through specialized receptors Sr-a and Cd36, among other mechanisms60. These 
processes evoke a characteristic inflammatory response by releasing inflammatory molecules, 
such as Mcp1, to the extracellular matrix (ECM), which recruit more macrophages. The lipid-
laden macrophages become foam cells and undergo necrotic cell death releasing intracellular 
components leading to a vicious cycle of chronic inflammation37. Subsequently, smooth muscle 
cells migrate to the lesion in response to inflammatory mediators and contribute to fibrotic 
plaque formation and rupture59.  
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Hepatosteatosis: Liver insulin resistance and hepatic steatosis, referred to as nonalcoholic fatty 
liver diseases (NAFLD), are major components of the metabolic syndrome. Lipidomic analyses 
of liver tissue during various stages of NAFLD show a strong correlation between abnormal fat 
composition and disease pathogenesis61 with excess fat accumulation leading to the recruitment 
of inflammatory cells62. Together with Kupffer cells, these immune cells are responsible for the 
development of hepatic inflammation in both humans and various animal models. Recent studies 
have shown that depletion of Kupffer cells or inhibition of pro-inflammatory mediators protect 
against the development of NAFLD63-65. During high fat diet treatment, depletion of Kupffer 
cells by GdCl3 or clodronate-encapsulated liposomes has been shown to improve insulin 
sensitivity and glucose tolerance66-68. A single dose of GdCl3 in mice on normal chow enhances 
insulin signaling and reduces glucose production in the liver67. In contrast, macrophage-specific 
Ppard–/– mice, whose macrophages/Kupffer cells exhibit a predominantly M1 phenotype, 
develop insulin resistance and hepatic steatosis69. 
 
Muscle Dysfunction: The resident macrophage population in muscle has not been characterized. 
Macrophages do, however, play a significant role in muscle repair during exercise and tissue 
damage70. Studies have shown that macrophages infiltrate fat depots formed around the muscle 
in obesity18. Additionally, muscle is a target for inflammatory cytokines from other tissues, such 
as liver and adipose tissue, even though it may not be a site of significant production of 
inflammatory mediators71.  
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INFLAMMATORY SIGNALING AND METABOLIC DISEASES 
Although the role of inflammation in atherogenesis is well documented37,58,59, the 
underlying mechanisms through which pro-inflammatory signaling pathways cause insulin 
resistance are still under investigation. One of the better-defined mechanisms is through c-Jun N-
terminal kinase (Jnk) activation, which phosphorylates insulin receptor substrate-1 (Irs1) to block 
insulin signal transduction8,72. Similarly, our knowledge regarding how anti-inflammatory 
pathways improve metabolic homeostasis is limited, apart from their ability to antagonize M1 
activation73. In this section, I will summarize various signaling pathways mediating macrophage 
activation during the pathogenesis of the metabolic syndrome. 
 
Pro-inflammatory signaling 
Jnk and Pro-inflammatory cytokines: Jnk is an important regulatory node for inflammatory 
mediators, including pro-inflammatory cytokines, toll-like receptors and endoplasmic reticulum 
(ER) stress (Fig. 2). In obesity-induced insulin resistance and hepatic steatosis, deletion of Jnk1 
in the hematopoietic compartment by bone marrow transplantation is beneficial74. Tnfα was one 
of the first pro-inflammatory cytokines to be linked to Jnk activation5,72. Tnfα receptor knockout 
mice show improved metabolic homeostasis and insulin sensitivity on both normal chow and 
high fat diet75. Additionally, Tnfa+/+ bone marrow donated to a Tnfa–/– mouse induces insulin 
resistance in an otherwise, insulin sensitive mouse76. Recently, double-stranded RNA-dependent 
protein kinase (Pkr), which senses viral infection, was shown to interact with Jnk and Irs177. 
Interestingly, Pkr is able to directly phosphorylate Irs1, suggesting that Jnk integrates different 
inflammatory signals through a multi-component inflammatory complex. 
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Toll-like receptors and Nf-κb: TLRs are pattern recognition receptors that respond to pathogenic 
antigens and propagate inflammatory signaling78. In vitro, free fatty acids (saturated fatty acids, 
e.g. palmitic acid) or ceramides can signal through Tlr2 and Tlr4 on macrophages and induce 
pro-inflammatory gene expression79-81. In vivo, whole body Tlr4 gene deletion improves insulin 
sensitivity in a lipid infusion model of transient insulin resistance. Similarly, Tlr4 loss of 
function mutation or Tlr2 deficiency protects against diet-induced obesity and insulin 
resistance82-84. However, Tlr2/4 are expressed on most tissue types including adipocytes and 
hepatocytes, in addition to immune cells. The contribution of macrophage Tlr4 was examined 
through hematopoietic cell-specific Tlr4 deletion, which ameliorates high-fat diet induced 
hepatic and adipose tissue insulin resistance85.  
Tlr4 ligation promotes Ikk activation, followed by phosphorylation and nuclear 
translocation of Nf-κb to activate inflammatory gene transcription. Systemic deletions of Nf-κb 
or various Ikk isoforms (e.g., Ikkβ and Ikkε) prevent obesity induced insulin resistance37,86,87. 
Myeloid specific Ikkβ deletion also leads to improved systemic insulin sensitivity, increased 
glucose disposal rate and suppressed hepatic glucose production86. In line with these 
observations, salicylate treatment, known to attenuate Nf-κb activation, increases insulin 
sensitivity in humans88-90. 
In the setting of atherosclerosis, many studies demonstrated that a complete deletion of 
various TLR family members reduces the lesion size in Ldlr–/– or Apoe–/– mice91,92. Ldlr–/– mice 
transplanted with Tlr2–/– bone marrow are protected from atherosclerosis91. Similarly, mice 
deficient in myeloid specific NF-κB subunit p50 have decreased atherosclerotic lesions in Ldlr–/– 
mice93. Lesions in these animals exhibit near complete loss of foam cells, supporting previous 
findings that Nf-κb regulates genes involved in lipid uptake and foam cell formation94.  
 
 
14 
Inflammasome: The Nlr family, pyrin domain containing 3 (Nlrp3) inflammasome senses 
endogenous danger signals and generates the mature, secreted forms of Il-1β and Il-18 through 
caspase 1 (Casp1) activation95-98. In vitro, palmitic acid and ceramide induce Il-1β and Casp1 
processing in the macrophage99. Mice deficient in Nlrp3 or Asc (an adaptor protein of the Nlrp3 
inflammasome) exhibit increased insulin sensitivity in liver, WAT and muscle99-101. In addition, 
Casp1 and Il-1β have been shown to mediate inflammasome induced insulin resistance100. Along 
these lines, lack of Il-1R, the receptor for Il-1β, confers protection against insulin resistance 
induced by a high-fat diet102. Inflammasome activation can also be detected in atherslerotic 
lesions103,104. Cultured macrophages exposed to crystalline cholesterol secrete Il-1β and Il-
18103,104. In concert, Ldlr–/– mice transplanted with bone marrow from mice lacking Nlrp3 or Asc 
show a reduction in the lesion area and Il-18 level103. 
 
ER Stress: The endoplasmic reticulum (ER) is the site of protein folding, vesicle transport and 
lipid synthesis. When ER capacity is overburdened, the unfolded protein response (UPR) is 
activated, as characterized by increased activities of Prkr-like endoplasmic reticulum kinase 
(Perk, also known as Eif2ak3), inositol-requiring 1 (Ire1, also known as Ern2), and activating 
transcription factor 6 (Atf6)105. Activation of the UPR through these signaling molecules leads to 
downstream CCAAT/enhancer-binding protein homologous protein (Chop, also known as 
C/ebpε) activation and subsequent induction of apoptosis. The initiation and propagation of the 
UPR and ER stress by obesity and metabolic stress have been reviewed in detail105. ER stress in 
adipose tissue or liver leads to insulin resistance, which is associated with activation of Jnk and 
Ikk, suggesting that ER stress is linked to inflammatory pathways105-107. In atherosclerosis, 
chronic activation of the ER stress pathway contributes to macrophage death and subsequent 
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plaque necrosis43. Chop expression and macrophage apoptosis have been correlated with 
advanced lesions108,109 and deletion of Chop suppresses lesional macrophage death/necrosis110. 
Lastly, it has been shown that the ER stress in the macrophage is caused by increased fatty acid 
binding protein 4 (FABP4, also known as aP2) lipid chaperone activity, which promotes 
atherogenesis111.  
 
Hypoxia: Activation of macrophages to a proinflammatory state increases glucose influx for 
glycolysis, which is controlled by hypoxia inducible factor (Hif)-1α112-115. Loss of Hif-1α in the 
macrophage leads to decreased pro-inflammatory cytokine production, while deletion of von 
Hipple-Lindau tumor-suppressor protein (Vhl), a repressor of Hif-1α, results in chronic 
activation of Hif-1α and uncontrolled inflammation114,116. In the context of metabolic 
dysregulation, adipose tissues in obese mice are hypoxic, which may cause macrophage Hif-1α 
activation52,53,117,118. Systemic hypoxia has been shown to induce insulin resistance and 
NAFLD52,119,120. Furthermore, high levels of hypoxia during adipose expansion may lead to 
necrotic death of both adipocytes and macrophages, since Hif-1α activation blocks physiological 
apoptotic cell death53,118,121. Similarly, hypoxia promotes macrophage necrosis in mouse models 
of atherosclerosis121-123.  
 
Anti-inflammatory signaling 
TH2 cytokines: The other end of the macrophage activity spectrum is the TH2 cytokine-induced 
alternative activation, characterized by the expression of M2 markers, such as Arg1, Mgl1, and 
Ym130,73. These macrophages function to repair damages elicited by pro-inflammatory M1 
macrophages. As discussed earlier, in the lean state, ATMs display an M2 phenotype, suggesting 
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that at the physiological level, M2 macrophages may play an important role in maintaining 
metabolic homeostasis50. In line with this notion, TH2 cytokines, notably Il-13, have been 
detected in WAT and liver124. Treatment of diet-induced obese mice with Il-4 significantly 
improves glucose homeostasis and insulin sensitivity, whereas deletion of signal transducer and 
activator of transcription 6 (Stat6), a TH2 effector, worsens insulin resistance125. In addition, mice 
infected with helminth worms, which induce an M2 response, exhibit improved insulin 
sensitivity126.  
 
Nuclear Receptors: Nuclear receptors are ligand activated transcription factors that control 
important biological processes127. Several lipid sensing nuclear receptors, such as the peroxisome 
proliferator activator receptors [Pparα, also known as Nr1c1; Pparδ, also known as Nr1c2; and 
Pparγ, also known as Nr1c3; activated by dietary fatty acids]128,129 and the liver X receptors 
[Lxrα, also known as Nr1h3 and Lxrβ, also known as Nr1h2; activated by cholesterol 
metabolites] are drug targets to treat metabolic diseases130,131. In the macrophage, Il-4/Il-13-
induced alternative macrophage activation is associated with increased fatty acid b-oxidation and 
oxidative metabolism124,132, pathways regulated by PPARs133. Accordingly, Pparδ and Pparγ 
have been shown to be induced by TH2 cytokines and control M2 activation124,134. Mice with 
myeloid specific deletion of Pparδ or Pparγ show increased M1 and decreased M2 markers in 
WAT and liver and develop systemic insulin resistance124,134-137. The M1/M2 paradigm is also 
relevant in Kupffer cells in the liver. Myeloid Pparδ deletion worsens hepatic steatosis in mice 
fed a high fat diet124,137. It has been shown that macrophages from these mice produce factors 
that promote adipocyte and hepatocyte dysfunction in vitro124. Earlier studies also demonstrated 
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an anti-inflammatory role for PPARs and LXRs, which correlates well with the athero-protective 
roles for these nuclear receptors138-140.  
 
GPCRs: Although saturated fatty acids are known to induce inflammatory signaling pathways, 
epidemiological studies show that Mediterranean diets high in polyunsaturated ω-3 (n-3) fatty 
acids actually reduce the incidence of metabolic diseases141-144. ω-3 fatty acid derivatives, such 
as docosahexanoic acid (DHA), eicosapentanoic acid (EPA) and resolvins, exhibit anti-
inflammatory activities145. DHA and EPA have been shown to bind to G-protein coupled 
receptor Gpr120 on macrophage surfaces. Gpr120 ligation inhibits the actions of Tnfα and 
reverses insulin resistance brought on by a high-fat diet146. Gpr120 and PPARs share several 
fatty acid ligands, suggesting potential crosstalk between these two signaling pathways147.  
 
METABOLIC CONTROL OF MACROPHAGE FUNCTION 
One of the main functions of the macrophage is to integrate a broad variety of stimuli to 
sense and eliminate those pathogenic signals that are either excessive or harmful to the host. 
Metabolites within the macrophage are critical for the ability of the macrophage to travel to sites 
of stimulation, respond efficiently and restore homeostasis. In fact, the host undergoes a state of 
transient insulin resistance during an infection, presumably in an effort to sequester energy for 
immune cell utilization, suggesting a critical role for metabolites in the immune cell response to 
pathogens148. Phagocytosis of a pathogen by the immune cell is a tightly regulated process in 
which macrophages can respond to and activate energy demanding cellular remodeling and 
signaling cascades (Fig. 4). Upon recognition, the pathogen is taken up into an invagination of 
the macrophage membrane149,150. This invagination detaches from the membrane by a series of 
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Figure 4: Phagocytosis and bacterial killing rapidly utilize ATP and NADPH. Phagocytosis of a pathogen requires 
several critical steps including recognition and uptake, fusion of the lysosome to the phagosome, phagosome 
acidification, and bacterial killing. Actin polymerization and hydrolysis of ATP aid in vesicular trafficking and 
membrane modification. NADPH oxidases and vacuolar ATPases utilize NADPH and ATP, respectively to generate 
protons and electrons that can be used to acidify the phagosome and generate ROS. Both of these processes 
contribute to efficiency of bacterial killing. Deficiencies in any of the processes involved in phagocytosis lead to 
increased susceptibility to infection.  
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actin polymerization events to become its own organelle known as the phagosome. The 
phagosome then goes through a series of fusion/fission events with the lysosome to acquire 
enzymes and proteins necessary for acidification and bacterial killing. These proteins 
cooperatively acidify and produce reactive oxygen species (ROS) within the phagosome151. 
Fusion and acidification processes are necessary to activate several enzymes that are only 
functional in an acidic environment. Through the activation of these enzymes and production of 
ROS, the macrophage is able to kill the ingested pathogen and break it down into small peptides 
that are presented to the adaptive immune system for development of memory against future 
invasions152-154. Phagocytosis therefore enables the macrophage to kill pathogens and clear debris 
within the organism in an effort to maintain systemic homeostasis.  
The maturation and acidification of the phagosome leads to the eventual degradation of 
the pathogen. Phagosomal ROS production by the NADPH oxidase 2 (Nox2) complex is 
required for efficient and complete bacterial killing155. The Nox2 complex consists of the 
membrane localized gp91phox (Nox2, also known as Cybb) protein and an associated protein 
cytochrome b-245, alpha polypeptide (Cyba, also known as p22phox) (Fig. 5a). Activation of the 
Nox2 complex is tightly regulated by spatial separation of the membrane associated catalytic 
Nox2/p22phox complex and its cytosolic activator complex that consists of an activator protein 
(neutrophil cytosolic factor 2 (Ncf2), also known as p67phox), organizer protein (Ncf1, also 
known as p47phox), Ncf4 (also known as p40phox), and the small GTPase Rac1. Association of 
the cytosolic complex with the membrane bound proteins creates a functional Nox complex that 
oxidizes NADPH and shuttles electrons across the membrane generating ROS within the 
phagosome156. Defects in any of the components of the Nox2 complex results in chronic 
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Figure 5: NADPH oxidase 2 regulation by its cytosolic activator complex. Nox2 is the main oxidase responsible for 
ROS production in the phagosome. Because of ROS cellular toxicity, ROS production by Nox2 is tightly regulated 
through temporal and spatial activation of activator complexes in the cytoplasm. (a) In the unstimulated state, Nox2 
(gp91phox) and p22phox reside on the cellular membrane. The activator complex, consisting of p47phox, p67phox, 
and p40phox, remains spatially separated in the cytoplasm. Upon pathogenic stimulation, the AIR domain of 
p47phox becomes phosphorylated and the PX associates with membrane bound lipids. These changes lead to 
association of the activator complex to the membrane bound catalytic complex and subsequent production of 
phagoomal ROS. The lack of an AIR domain and differential lipid specificities of the PX domain compared to 
p47phox suggest an alternate role for Noxo1 in ROS production. As such, the reason for transcriptional activation of 
the Noxo1/Noxa1 complex in response to pathogenic stimuli is unclear. In chapter 4, I show that Ppars can regulate 
Noxo1 transcriptional activation. The significance of this regulation is unclear.  (b) Comparison of protein domains 
contained within p47phox and Noxo1.  
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granulomatous disease (CGD) and renders patients susceptible to bacterial and fungal 
infections157,158.   
High-energy molecules, such as adenosine triphosphate (ATP) and nicotinamide adenine 
dinucleotide phosphate (NAD(P)H), are crucial for the substrate driven activities of enzymes 
involved in various processes such as phagocytosis, movement, and cytokine production. In 
addition to the catabolism of glucose for the production of ATP, significant changes occur in the 
production and utilization of other metabolites, such as lipids and amino acids (Fig. 6). The 
many roles that metabolites play in macrophage activation and function are detailed below.  
 
ATP and NADPH: Perhaps the most apparent metabolic alteration between proinflammatory and 
anti-inflammatory macrophages is the switch between anaerobic and aerobic catabolism of 
glucose for generation of high-energy molecules. During proinflammatory activation, production 
of ATP occurs in the macrophage primarily through anaerobic respiration in the cytoplasm159. 
This is controlled by a switch from the liver type 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 1 (Pfkfb1, also known as Pfk2) to the more ubiquitous and active form Pfkfb3 
(also known as uPFK2)160. Activation of Pfkfb3 helps to maintain higher concentrations of 
fructose-2,6-bisphosphate which allosterically activates phosphofructokinase 1 (Pfk1). When 
activated in this manner, Pfk1 has an increased affinity for fructose-6-phosphate and decreased 
inhibition by ATP160. Additionally, Hif-1α is activated and there is an increase in lactate 
dehydrogenase (Ldhb) activity161,162. Together, these changes shunt glucose into lactate 
generation and anaerobic respiration. Evolutionarily, this is thought to occur because the cell 
requires a large and rapid burst of energy to undergo functions such as bacterial killing, actin 
 
 
22 
 
Figure 6: Dietary lipids and inflammatory mediators share common signaling pathways in the control of 
macrophage metabolism.  The TH1 (M1) type macrophage response, elicited by inflammatory cytokines, bacterial 
surface proteins, and saturated fatty acids, can induce metabolic changes that promote an anaerobic and reductive 
environment. The most notable change involves the switch to lactate production and anaerobic respiration. While 
energetically unfavorable, this state allows for rapid and large energy bursts that can be used for bacterial killing by 
production of ROS and other mediators. In contrast, cytokines Il-4 and Il-13, parasitic worm infection, and 
unsaturated fatty acids induce metabolic changes that induce an oxidative state capable of sustaining long term 
repair and tissue homeostasis. These macrophages rely primarily on fat burning to generate energy and produce 
mediators critical for resolution 
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polymerization, transcription and translation. In contrast to the very energy demanding 
proinflammatory macrophage, anti-inflammatory macrophages rely on oxidative glucose and 
fatty acid metabolism to generate more sustained and constant energy sources for tissue 
remodeling and repair163.  
ATP is a critical cofactor for intracellular energy transfer. ATP hydrolysis leads to the 
release of one or more high-energy phosphate groups that can be transferred to other pathways 
for use. ATP is critical for a majority of cellular functions from generation of macromolecules to 
cell division and movement. During a bacterial infection, ATP is most rapidly utilized by the 
macrophage for cellular kinesis and the oxidative burst164,165. ATP is hydrolyzed during actin 
polymerization, thereby allowing the cell to move to its given target. Additionally, actin plays a 
critical role in membrane invagination, phagosome formation, and phagosome-lysosome 
fusion164. ATP is also rapidly hydrolyzed by the vacuolar ATPase, a membrane bound protein 
complex that shuttles the released electrons across the phagosomal membrane to produce the 
oxidative burst165.  
In addition to ATP generation, NADPH is an important molecule that is required for 
critical enzymatic activities during bacterial killing. NADPH is generated in the pentose 
phosphate pathway (PPP) in the reactions catalysed by glucose 6 phosphate dehydrogenase 
(G6pdh) and phosphogluconate dehydrogenase (Pgd). There is evidence that immune stimulated 
glucose uptake is tightly coupled to increased PPP activity 159. The PPP uses a three-enzyme 
oxidative process to convert glucose-6-phosphate to ribulose-5-phosphate that is used for further 
metabolic reactions, generating 2 molecules of NADPH from NADP+ reduction. The first step of 
the PPP is rate-limiting because of the allosteric role of NADPH in regulating G6pdh activity166. 
NADPH can also be generated through activities of malic enzyme and isocitrate dehydrogenase, 
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but these enzymes do not generate enough NADPH to independently maintain cellular 
processes159,166. Once generated, NADPH is used for several pathways critical for bacterial 
killing. On the phagosomal membrane, NADPH is oxidized to NADP+ by the enzyme NADPH 
oxidase to generate ROS within the phagosome (Fig. 5a)167. NADPH is also a critical cofactor 
for many enzymes involved in de novo lipogenesis, antioxidant systems, and nitric oxide 
regulation, which are also modulated by and alter the outcome of bacterial infections166.  
 
Lipids and Lipid Mediators: Lipids play a critical role in macrophage activation and function. 
Not only can they be taken up and oxidized for energy, as is observed in Il-4 stimulated 
macrophages, but lipids themselves can be generated during phagocytosis through an increase in 
de novo lipogenesis168,169. Lipids are also critical signaling molecules during the activation of 
various enzyme complexes in the cell, including the NADPH oxidase. While the origin of the 
lipids is unclear, they typically reside in the cellular membrane and interact with proteins to 
provide scaffolds for spatial activation or to directly activate target proteins. For example, PIP3 is 
the best studied signaling lipid that resides in the cellular membrane and is critical for Akt 
activation both in the context of infection and insulin signaling in many tissue types170. 
Additional lipids have since been identified that can differentially regulate activation of proteins. 
For example, specificity of NADPH oxidase activation occurs through lipid binding of the 
organizer protein, either neutrophil cytosolic factor 1 (Ncf1, also known as p47phox) or NADPH 
oxidase organizer 1 (Noxo1), to lipids found on the cellular membrane (Fig. 5b). These 
membrane lipids associate with the phosphoinositide-lipid binding (PX) domain found towards 
the N-terminal end of either organizer protein. Several studies suggest that differences in the PX 
domain of p47phox and Noxo1 specify binding of these two proteins to their respective lipids, 
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thereby leading spatial and temporal control of NADPH complex activation171,172. While lipids 
have been shown to play a role in macrophage function, improved lipidomic techniques will help 
to identify the source of these lipids and the importance of unique lipid species as signaling and 
structural molecules.  
Lipid mediators secreted from macrophages are critical for signaling cascades, cell 
survival and resolution. At a transcriptional level, pro- and anti-inflammatory macrophages 
exhibit differential regulation of enzymes involved in eicosanoid production. For example, pro-
inflammatory macrophages show marked upregulation of prostaglandin-endoperoxide synthase 2 
(Ptgs2, also known as Cox2), the consequence of which is an increase in inflammation. 
Concurrently, these cells suppress enzymes such as Ptgs1 (also known as Cox1), leukotriene A4 
hydrolase, thromboxane A synthase 1, and arachidonate 5-lipoxygenase (Alox5)173, which 
produce downstream lipid mediators that promote cellular repair and resolution. Conversely, in 
an Il-4 stimulated macrophage, Cox1 and Alox5 are upregulated as a mechanism to promote 
resolution and suppress inflammation173. Sphingosine, ceramide kinases, and sphingosine 
mediators are also differentially regulated by activated macrophages, thereby promoting pro-
inflammatory or pro-resolution environments173.   
 
Amino Acids: Epidemiologic data shows that deficiencies in dietary protein or amino acids are 
associated with impaired immune function and increased susceptibility to infectious diseases. 
Amino acids, derived from the diet or endogenously synthesized, are converted to critical 
mediators through many complex processes. The derived products have many important roles in 
signaling, inflammatory responses, and resolution. For example, L-Arg is metabolized by Nos2 
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to produce nitric oxide (NO), an important microbicidal molecule. Alternatively, when arginase 
1 (Arg1) is highly expressed, as is the case in anti-inflammatory macrophages, L-Arg is 
converted to ornithine, which contributes to collagen synthesis, cell proliferation, and tissue 
remodeling174. The end product of tryptophan metabolism, nicotinamide adenine dinucleotide 
(NAD), promotes Tnf synthesis in a sirtuin 6 (Sirt6) dependent manner175. Levels of glutathione, 
a derivative of L-cysteine, L-glutamic acid, and glycine, are differentially regulated in pro- and 
anti-inflammatory macrophages. As a molecule that can be oxidized and reduced, glutathione 
acts as a mechanism for the cell to reduce cellular toxicity176-178. These examples are only a few 
ways in which amino acids contribute to macrophage function and bacterial killing. While many 
of the mechanisms are clear, more work is needed to understand the intricate relationship 
between amino acids and cellular functions in the macrophage.  
 
Micronutrients: Micronutrients such as vitamin D, iron, zinc, and copper have been shown to 
play a critical role in immune function. Epidemiological data suggest that a deficiency in any of 
these micronutrients makes the host more susceptible to infections. Below are two examples of 
the mechanism by which micronutrients can direct bacterial killing. However, many more 
micronutrients influence microbicidal activity, with some of the mechanisms more defined than 
others. During infection, macrophages undergo changes to retain iron to support bacterial killing. 
For example, by increasing levels of ferretin, the macrophage is able to release free iron which 
can be utilized during the respiratory burst to enhance free radical release179. Additionally, 
alterations in total cellular iron levels can greatly affect NADPH oxidase function and the 
respiratory burst. Iron loading also influences NO release and Nos2 activity. Conversely, 
macrophages that are resolving inflammation or repairing damaged tissue display a phenotype of 
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iron export that supports matrix remodeling and cellular proliferation180. While these 
mechanisms by the macrophage to regulate iron homeostasis appear to be in an effort to protect 
the host, they also serve to sequester iron from the pathogen. Because of the dependance of many 
pathogens on iron uptake from the host, it has been suggested that evolutionary mechanisms may 
function to sequester iron such that uptake by pathogens is restricted179.  
 While the role of iron in bacterial killing is well studied, the functions of other 
micronutrients are less understood. Evidence suggests that both silver and copper have been used 
as anti-microbial agents since documentation of medical practices began. It has been shown that 
copper receptors on the surface of macrophages are increased post infection and copper is taken 
up into the macrophage181. There is evidence that copper helps mediate ATPase activity and 
contributes to the respiratory burst. This data is supported by the notion that macrophages from 
patients with copper deficiency display decreased levels of ROS within the phagosome that is 
associated with a suppressed respiratory burst182,183. Copper is also believed to be antimicrobial 
because of the toxic effects of copper in bacteria181. However, in an effort to survive the insult of 
copper, many pathogens have developed methods to promote copper export and avoid toxicity. 
Despite this, copper is still a potent antimicrobial agent. Because of the critical role of 
micronutrients in cell survival, both the pathogen and the host have developed mechanisms to 
utilize and defend against micronutrients. Understanding these mechanisms provides insight into 
metabolic and immune function.   
SIGNIFICANCE AND PREVIEW 
 In many contexts, immune cells and metabolic tissues rely on each other in a 
physiological setting and dysregulation of either of these processes leads to pathologic disease 
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states. With current therapeutics aimed at restoring homeostasis, it is crucial to understand the 
mechanisms by which immune cells and metabolic tissues communicate. This dissertation seeks 
to elucidate the relationship between metabolic pathways, immune cells, and pathogens to help 
us discover novel targets for complex diseases. Additionally, understanding the effects of 
immunomodulatory compounds on immune activation and systemic metabolism can lend insight 
into the effects of therapies targeted at chronic inflammatory diseases.  
In this thesis, I seek to understand the functional relationship between immune and 
metabolic signaling pathways in an effort to develop therapeutics for multifaceted metabolic and 
immune pathologies (Fig.7). In the first two chapters, I will detail the therapeutic potential of 
parasite derived host-like glycans in controlling metabolic dysfunction associated with chronic 
inflammation. I demonstrate in chapter 2 that administration of lacto-N-fucopentaose III 
(LNFPIII), a LewisX containing immunomodulatory glycan found in human milk and on the 
helminth egg improves glucose tolerance and insulin sensitivity in diet-induced obese mice. This 
effect is mediated partly through increased Il-10 production by LNFPIII activated macrophages 
and dendritic cells, which reduces white adipose tissue inflammation and sensitizes the insulin 
response of adipocytes. In chapter 3, I show that LNFPIII treatment up-regulates nuclear receptor 
Fxrα to suppress lipogenesis in the liver, conferring protection against hepatosteatosis. At the 
mechanistic level, the extracellular signal-regulated kinase (Erk)-AP1 pathway appears to 
mediate the effects of LNFPIII on both inflammatory and metabolic pathways. Together, these 
results suggest that LNFPIII/LewisX may provide novel therapeutic approaches to treat metabolic 
diseases. The data also suggest a potential role for modulation of metabolic pathways as a 
treatment for schistosomiasis and other parasitic infections. This concept led to the work done in 
chapter 4.  
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Figure 7: Immune systems, metabolic systems, and non-self pathogens interact to maintain homeostasis. The 
interactions of non-self pathogens with the immune system are well documented. Recent studies have shown 
crosstalk between immune systems and metabolic systems. In chapter 2, I show that pathogen derived products can 
influence immune function and subsequently alter metabolic function within the host. Chapter 3 addresses the direct 
interactions of non-self pathogens with the metabolic system. The interaction between metabolic regulation in the 
immune system and pathogens is discussed in chapter 4. Understanding the relationship between these three systems 
is critical for developing therapeutics that can maintain the careful homeostatic balance dictated by evolution for 
physiological health.   
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In the fourth chapter, I address the hypothesis that metabolic pathways are required for 
proper bacterial killing within the macrophage. In chapter 4, I show that the lipid sensing nuclear 
receptor Pparδ controls key genes in phagosomal ROS production to promote bacterial 
clearance. Lack of Pparδ in the macrophage prevents efficient killing of Streptococcus 
pneumoniae, the causative bacterium in many cases of respiratory pneumonia. In contrast, Pparδ 
activation improves animal survival after bacterial infection. My data reveal an unexpected role 
for Pparδ in the control of innate immunity and identifies a therapeutic target to improve the 
outcome of bacterial infections. Together, this thesis work identifies several critical mechanisms 
by which immune signaling and metabolic signaling pathways intersect with the potential of 
developing therapeutics for improving host outcome to infections and environmental 
pathologies.  
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CHAPTER 2 
Immunomodulatory glycan LNFPIII improves WAT insulin sensitivity 
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Introduction 
 Metabolic syndrome is a major medical and economic concern worldwide. Chronic 
inflammation is a key contributor of pathologies associated with metabolic diseases, such as 
insulin resistance/type 2 diabetes, atherosclerosis and nonalcoholic fatty liver diseases. Although 
features of chronic “metabolic-related inflammation” differ from those of acute inflammatory 
responses to exogenous insults, studies have shown that several pathogen sensing mechanisms of 
innate immunity are negative regulators of insulin sensitivity184. For example, pattern recognition 
receptors and downstream effectors [e.g., toll-like receptor-4 (Tlr4), IκB kinase β (Ikkβ) and 
Ikkε, Tnfα and double-stranded RNA-dependent protein kinase (Pkr)] have been shown to be 
activated by high fat feeding and to induce metabolic diseases71,77,80,86,87. In addition, activation 
of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 
(Nlrp3) inflammasome185, possibly in response to lipid metabolites (e.g., fatty acids and 
ceramides)99,101, results in the cleavage of pro-caspase-1 (pro-casp-1) and release of mature Il-1β, 
which causes insulin resistance99-101.  
Resident macrophages and lymphocytes in white adipose tissue (WAT) and liver are 
believed to play important roles in metabolic-related inflammation124,137,186-188. As described in 
detail in the introduction, TH2 cytokine driven anti-inflammatory macrophages play a critical role 
in maintaining local and systemic insulin sensitivity50. Subsequent studies have identified several 
sources of T helper type 2 (TH2) cytokines (e.g., Il-4 and Il-13) within WAT that mediate 
alternative activation124,126,188. Depletion of TH2 cytokine producing cells or the downstream 
mediators in macrophages leads to insulin resistance124,134,188. In contrast, increased TH2 cytokine 
production, as seen in helminth infection, improves glucose homeostasis126. While it remains 
unclear how TH2-biased and/or anti-inflammatory immune responses improve metabolic 
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homeostasis, over-expression of the anti-inflammatory cytokine Il-10 has been shown to improve 
insulin sensitivity189. 
 The ability to drive TH2-type and anti-inflammatory responses during helminth infection 
has been associated with decreased damage to host tissues, prolonging host survival190. During 
infection with Schistosoma mansoni (S. mansoni), parasite eggs trapped in host tissues such as 
the liver, are the main stimuli for TH2 cytokine production in mice191. Injection of a saline 
soluble homogenate of eggs (or soluble egg antigen, SEA) is sufficient to induce TH2-biasing of 
the immune response192. Subsequently, it was shown that glycans and glycoproteins found in 
SEA, such as the LewisX containing Lacto-N-fucopentaose III (LNFPIII), GalNAcβ1-4GlcNAc 
(LacdiNAc), fucosylated LacdiNAc and omega-1 (a T2 Rnase), are capable of mediating the 
immunomodulatory activity193-199. Notably, LNFPIII is one of the major sugars found in human 
milk post-partum and is thought to play a similar protective role in the neonate200,201. These 
observations suggest that during co-evolution with human hosts, S. mansoni parasites expressing 
immunomodulatory glycans were able to escape detection and had a developmental 
advantage202,203. In fact, macrophages treated with LNFPIII exhibit a TH2 cytokine-independent, 
M2-like phenotype, characterized by the expression of the M2 markers, arginase 1 (Arg1) and 
chitinase 3-like 3 (Ym1, also known as Chi3l3)204. LNFPIII and other helminth derived glycans 
induce Il-10 production205, up-regulate T regulatory cell numbers206 and inhibit bacterial 
lipopolysaccharide induced inflammatory responses205. The mechanisms through which LNFPIII 
exerts these anti-inflammatory activities remain poorly characterized. It has been shown that 
LNFPIII signals through several C-type lectin receptors (CLRs)207 and Tlr4208, which leads to 
activation of Erk. Although helminth infections polarize the immune response towards the TH2 
type, studies have shown that it reduces, rather than exacerbates, the incidence of allergic 
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responses, possibly because of the regulatory activity of Il-10209,210.   
In the current study, I seek to further characterize the unique immunomodulatory activity 
of LNFPIII and determine whether LNFPIII is effective in dampening chronic inflammation and 
improving metabolic function in a diet induced model of type 2 diabetes. My results show 
LNFPIII or SEA treatment reduced inflammation and increased insulin sensitivity in WAT in an 
Il-10-dependent manner.  
 
Results 
LNFPIII treatment improves insulin sensitivity  
LNFPIII has been shown to induce M2-like macrophage activation, independent of TH2 
cytokines204. I confirmed that LNFPIII treatment up-regulated Arg1, Ym1 and macrophage 
galactose-type C-type lectin-1 (Mgl1, also known as Cd301) expression, albeit to a lesser extent 
than Il-4, in macrophages (Fig. 8a). In contrast, LNFPIII was more effective than Il-4 in 
inducing Il10 expression and release into macrophage conditioned media (CM) (Fig. 8a and 8b, 
and Supplementary Fig. 1a). This effect was blunted when macrophages were treated with 
PD98059 to block the activity of Erk, which has been implicated in mediating LNFPIII signal 
transduction (Fig. 8b)205,208,211. I also found LNFPIII increased Il-10 production in dendritic cells 
in an Erk dependant manner (Supplementary Fig. 1b). The ability of LNFPIII to upregulate Il10 
expression was independent of Stat6 and Pparδ (known effectors of TH2 cytokines, 
Supplementary Fig. 1c). Taken together, LNFPIII induces an anti-inflammatory state that 
increases Il-10 production. To determine whether the immunomodulatory activity of LNFPIII 
might be beneficial for treating metabolic diseases thought to be associated with chronic 
inflammation, I injected 8-week-old male mice (C57BL/6J) with vehicle or LNFPIII (25  
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Figure 8 LNFPIII increases Il-10 production and improves insulin sensitivity. (a) Real-time q-PCR examining the 
expression of M2 (alternative activation) genes in bone marrow derived macrophages treated with Il-4 (20 ng ml–1) 
or LNFPIII (20 µg ml–1) for 24 hr. (b) Il-10 concentrations in conditioned medium from LNFPIII or vehicle treated 
macrophages determined by ELISA. PD98059 (10 µM): Erk inhibitor. (c) Serum Il-10 and Il-4 concentrations in 
vehicle or LNFPIII treated mice (n = 5–7 per treatment) (d and e) Glucose tolerance test (GTT, d) and insulin 
tolerance test (ITT, e) in vehicle and LNFPIII treated mice. Inset in (e): homeostasis model of assessment-insulin 
resistance (HOMA-IR). (f) Western blot analyses to examine insulin stimulated Akt phosphorylation in WAT from 
vehicle and LNFPIII treated mice (from four individual mice per treatment). P-Akt: phospho-Akt; t-Akt: total Akt. 
(g) The relative level of p-Akt to t-Akt in WAT ± insulin injection quantified by densitometry based on Western 
signals in (f) or by ELISA-based assays. Values are expressed as means ± s.e.m. For in vitro assays, the mean and 
s.e.m. were determined from 3–4 biological replicates for a representative experiment. Experiments were repeated 3 
times. In vivo studies were reproduced in three mouse cohorts (n = 5–7 per treatment). Insulin signaling was 
examined in two of the three cohorts.  *P < 0.05 (LNFPIII or Il-4 versus vehicle control). 
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µg,twice a week) for 4–6 weeks after onset of high fat diet (HFD)-induced obesity and metabolic 
dysfunction. Consistent with the in vitro study, LNFPIII treated mice had higher circulating 
concentrations of Il-10 but the same concentration of Il-4 compared to vehicle treated mice(Fig. 
8c). When subjected to glucose tolerance test (GTT), LNFPIII treated mice showed significantly 
higher glucose handling capability compared to vehicle-treated control group(Fig. 8d; area under 
the curve (AUC), vehicle=36,727.5±1,769.13 (mean ± s.e.m.); LNFPIII=29,244±1,119.7, 
P=0.02). LNFPIII treatment also led to higher insulin sensitivity compared to vehicle treatment, 
as demonstrated by reductions in fasting serum insulin concentrations (vehicle, 1.54 ± 0.07 ng 
ml-1; LNFPIII: 1.29±0.06 ng ml–1, P<0.05) and improvements in both the results of insulin 
tolerance tests (ITT) and the homeostasis model of assessment-insulin resistance (HOMA-IR) 
(Fig. 8e. AUC, vehicle=123.58±4.79; LNFPIII=98.23±3.30, P=0.04). Enhanced insulin 
signaling, based on insulin stimulated Ser473 Akt phosphorylation (p-Akt), was observed in 
WAT but not in liver or muscle after acute insulin injection through the portal vein (Fig. 8f–g 
and data not shown). I conducted parallel metabolic studies with SEA treatment, which increased 
both blood Il-10 and Il-4 concentrations (Supplementary Fig. 1d). HFD-fed mice treated with 
SEA also showed an improved insulin response compared to vehicle-treated mice, as determined 
by GTTs, ITTs, fasting insulin concentrations and HOMA-IR (Supplementary Fig. 1e–g). 
Treatment with LNFPIII or SEA did not affect body weight, food intake or circulating 
concentrations of lipids and adiponectin (Table 1). These studies demonstrate the potential of 
using glycans derived from S. mansoni egg extract, including LNFPIII, to improve glucose 
homeostasis and insulin sensitivity. 
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Table 1. Metabolic parameters of wt mice treated with SEA and LNFPIII 
Serum samples were collected after 6 hr fasting. *P<0.05. Values displayed as mean ± s.e.m.  
n=6/group
Treatment Vehicle SEA Vehicle  LNFPIII 
Body weight (g) 43.63 ± 1.74 41.62 ± 1.36 45.26 ± 0.94 46.86 ± 1.09 
WAT/body weight 0.044 ± 0.0044 0.068 ± 0.002* 0.031 ± 0.015 0.039 ± 0.001 
Liver/body weight 0.042 ± 0.004 0.041 ± 0.003 0.038 ± 0.002 0.043 ± 0.002 
Triglyceride (mg dL–1) 102.38 ± 3.89 130.78 ± 7.52 67.17 ± 2.01 69.79 ± 1.18 
Free fatty acid (mmol L–1) 1.06 ± 0.05 1.14 ± 0.04 1.08 ± 0.08 1.02 ± 0.03 
Cholesterol  (mg dL–1) 165.90 ± 8.59 166.78 ± 12.35 154.72 ± 14.06 144.24 ± 15.99 
Glucose (mg dL–1) 221.67 ± 15.17 221.17 ± 8.53 236.2 ± 18.45 217 ± 12.01 
Insulin (ng mL–1) 1.002 ± 0.156 0.615 ± 0.081* 1.545 ± 0.065 1.288 ± 0.059* 
Adiponectin (mg mL–1) 5.92 ± 0.16 6.35 ± 0.13 5.59 ± 0.32 5.84 ± 0.10 
 
 
38 
LNFPIII enhances WAT insulin signaling through Il-10 
The interaction between resident macrophages and adipocytes plays an important role in 
adipose tissue metabolic homeostasis124. WAT histological analyses demonstrated that mice 
given LNFPIII had lower numbers of CLSs and reduced expression of F4/80 (a macrophage 
marker, also known as Emr1; Fig. 9a and 9b) compared to vehicle-treated mice. In addition, Il10 
and M2 genes (Arg1 and Mgl1) were upregulated and Tnfα and genes encoding the 
inflammasome pathway (Casp1, Nlrp3, Il18, and Il1b) were down-regulated (Fig. 9b). 
Consistent with the increased insulin sensitivity, the expressions of insulin receptor β (InsRb), 
insulin receptor substrate 2 (Irs2), CCAAT/enhancer binding protein α (C/ebpa), glucose 
transporter 4 (Glut4, also known as Slc2a4) and lipogenic genes were up-regulated in WAT from 
LNFPIII treated mice than vehicle-treated control mice (Fig. 9c). C/ebpα and Irs2 protein 
abundances were also higher in these mice than in controls (Fig. 9d). I obtained similar  results 
in SEA-treated cohorts of mice (Supplementary Fig. 2). Of note, SEA induced Arg1 expression 
in WAT to a greater extent than did LNFPIII, reflecting the fact that SEA treatment increased 
serum Il-4 concentrations (Supplementary Fig. 1d). These data support the notion that LNFPIII 
modulates WAT resident macrophage inflammation and improves adipose tissue metabolic 
homeostasis. 
Both in vitro and in vivo studies demonstrated that LNFPIII induced an anti-inflammatory 
phenotype characterized by elevated Il-10 concentrations, a cytokine that has  been shown to 
improve metabolic homeostasis189. To address whether the insulin-sensitizing effect in WAT is a 
direct action of the glycan or mediated by Il-10, I cultured 3T3-L1 adipocytes with or without 
LNFPIII or recombinant Il-10 (rIl-10). I observed that rIl-10, but not LNFPIII itself, improved 
insulin responsiveness, as determined by insulin-stimulated Akt phosphorylation, glucose uptake 
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Figure 9 Reduced inflammation and enhanced insulin signaling in WAT of LNFPIII treated mice. (a) Left panel: 
WAT histology showing crown-like structures (CLS, indicated with arrows). Scale bar: left images = 200 µm; right 
images = 50 µm. Right panel: CLSs quantified in 90 fields from 30 sections (3 fields per section) for each individual 
animal (n = 4 per group). Y-axis: % fields that contains certain percentage of CLSs; X-axis: % CLS-containing 
adipocytes in a given field; n.d: not detected. (b) Real-time q-PCR analyses of M1 and M2 gene expression in WAT 
of vehicle- and LNFPIII-treated mice (n = 5 per treatment). (c) Metabolic gene expression in WAT determined by 
real-time q-PCR. (d) Western blotting showing C/ebp-α and Irs2 protein levels in WAT. Bottom panel: relative 
C/ebp-α and Irs2 levels normalized to tubulin. Values are expressed as means ± s.e.m. Metabolic studies were 
reproduced in three mouse cohorts (n = 5–7 per treatment). Crown-like structures and expression analyses were 
examined in one and three of the three cohorts, respectively. *P < 0.05 (LNFPIII versus vehicle). 
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and lipogenesis (Fig. 10a). Conditioned medium from LNFPIII- primed wild type (wt) 
macrophages, which contained higher Il-10 concentrations than vehicle-primed conditioned 
medium (Fig. 8b), was able to reproduce the insulin-sensitizing activity in 3T3-L1 adipocytes, an 
effect that was abrogated in conditioned medium from LNFPIII-primed Il10–/– macrophages 
(Fig. 10b). Furthermore, conditioned medium derived from LNFPIII-primed wt, but not Il10–/–, 
macrophages induced the expression of InsR, Irs2 and C/ebpa and suppressed Il1b and Tnfa in 
3T3-L1 adipocytes (Fig. 10c). Reconstitution of rIl-10 in CM from Il10–/– macrophages restored 
its ability to improve insulin-stimulated glucose uptake and modulate metabolic and 
inflammatory gene expression (Fig. 10b,c). In vivo, LNFPIII was unable to improve insulin 
tolerance (Fig. 10d and Table 2), enhance insulin stimulated glucose uptake (Fig. 10e) and 
inhibit WAT inflammation (Supplementary Fig. 3a-b) in Il10–/– mice. In addition, Il10–/– mice 
were more insulin resistant than wt control mice (Supplementary Fig. 3c). Reciprocally, rIl-10 
injections (1 µg every other day for three total doses) improved glucose tolerance and insulin 
sensitivity and recapitulated the WAT phenotype observed in LNFPIII-treated mice 
(Supplementary Fig 3d–h and Table 3). Taken together, the results suggest that Il-10 is 
required for LNFPIII mediated improvement in WAT insulin signaling and systemic glucose 
homeostasis.  
 
Discussion 
 In this chapter, I demonstrate that LNFPIII treatment in obese mice shifts the immune 
profile to an anti-inflammatory state and decreases macrophage infiltration into WAT. This 
effect is, in part, driven by macrophage-derived Il-10, which inhibits inflammation and enhances 
the insulin response in WAT. 
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Figure 10 LNFPIII primed macrophage conditioned medium improves insulin sensitivity in 3T3L1 adipocytes in an 
Il-10 dependent manner. (a) Top panel: Western blotting showing protein levels of total Akt (t-Akt) and insulin 
stimulated Akt phosphorylation (p-Akt) in 3T3-L1 adipocytes treated with vehicle, LNFPIII or rIl-10 (representative 
samples from three experiments each with three biological replicates). Bottom left panel: insulin stimulated glucose 
uptake determined using radioactive 2-[H3]deoxy-D-glucose. Bottom right panel: cellular triglyceride contents 
measured at day 6 of 3T3-L1 adipocyte differentiation. Vehicle controls for LNFPIII (20 µg ml–1) and Il-10 (10 ng 
ml–1) were dextran and PBS, respectively. (b) Top panel: Western blotting showing protein levels of t-Akt and 
insulin stimulated p-Akt in adipocytes treated with control and conditioned medium (CM) from LNFPIII primed wt 
and Il10–/– macrophages. Bottom panel: insulin stimulated glucose uptake in adipocytes. (c) Gene expression in 3T3-
L1 adipocytes determined by real-time q-PCR. (d) Insulin tolerance test in vehicle and LNFPIII treated Il10–/– mice 
(n = 6 per treatment per genotype). AUC: area under the curve of ITT. (e) Ex vivo glucose uptake assay performed in 
adipose tissue slices collected before and after portal vein injection of 5 U kg–1 insulin. Values are expressed as 
means ± s.e.m. For in vitro assays, the mean and s.e.m. were determined from 3–4 biological replicates for a 
representative experiment. Experiments were repeated three times. Studies in Il10–/– and control mice were 
conducted in one cohort (n = 6). *P < 0.05 (treatment versus control).  
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                     Table 2. Metabolic parameters of Il10–/– mice treated with LNFPIII 
 
 
Serum samples were collected after 6 hr fasting. *P<0.05.       
Values displayed as mean ± s.e.m.  n=6/group  
                           Table 3. Metabolic parameters of wt mice treated with rIl-10 
 
Serum samples were collected after 6 hr fasting. *P<0.05.                           
Values displayed as mean ± s.e.m.  n=6/group 
Treatment Vehicle LNFPIII 
Body weight (g) 33.67 ± 3.84 37.03 ± 4.14 
WAT/body weight 0.019 ± 0.004 0.028 ± 0.005 
Liver/body weight 0.038 ± 0.002 0.032 ± 0.003 
Triglyceride (mg dL–1) 29.11 ± 1.11 36.14 ± 3.61 
Free fatty acid (mmol L–1) 0.49 ± 0.05 0.54 ± 0.08 
Cholesterol  (mg dL–1) 136.36 ± 10.87 153.89 ± 19.95 
Glucose (mg dL–1) 132.17 ± 17.36 142.5 ± 16.42 
Insulin (ng mL–1) 0.260 ± 0.033 0.259 ± 0.048 
Treatment Vehicle rIL-10 
Body weight (g) 31.93 ± 1.75 32.67 ± 1.03 
WAT/body weight 0.025 ± 0.001 0.032 ± 0.001* 
Liver/body weight 0.036 ± 0.001 0.035 ± 0.001 
Triglyceride (mg dL–1) 76.69 ± 5.04 84.83 ± 4.2 
Free fatty acid (mmol L–1) 0.57 ± 0.04 0.61 ± 0.06 
Cholesterol  (mg dL–1) 106 ± 3.80 104.21 ± 4.31 
Glucose (mg dL–1) 226.5 ± 11.93 228 ± 8.47 
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The hygiene hypothesis attributes the increased incidence of autoimmune diseases and 
allergic responses in developed countries to reduced human contact with pathogens212. A special 
emphasis has been on the interaction between parasitic worms and humans212,213; in addition to 
the TH2-biasing immune phenotype, helminth infections induce the proliferation of regulatory T 
cells and production of the anti-inflammatory cytokine Il-10214. My data show that LNFPIII 
treatment is sufficient to increase Il-10 production in macrophages and dendritic cells. 
Regulatory T cells are likely another major source of Il-10214. These cells are enriched in fat 
tissues from lean individuals and play a role in maintaining WAT function186. Anti-inflammatory 
pathways are thought to improve metabolic homeostasis primarily through attenuating the action 
of pro-inflammatory signaling (e.g., Tnfα and Il-1β). Overexpression of Il-10 in the muscle was 
shown to improve systemic insulin resistance through suppression of inflammation189. I find that 
in an Il-10 dependent manner, conditioned medium from LNFPIII treated wt macrophages 
directly enhanced insulin responses in adipocytes by up-regulation of InsR and Irs2 and 
increased insulin mediated glucose uptake and lipogenesis. Acute rIl-10 injection in HFD-fed 
mice also improved glucose homeostasis. Of note, short-term rIl-10 treatment did not appear to 
affect WAT macrophage infiltration (data not shown), suggesting that the insulin sensitizing 
effect of Il-10 can be separated from its anti-inflammatory activity.  
In line with this notion, several studies have identified IL10 polymorphisms associated 
with insulin resistance/type 2 diabetes in humans38,215,216. Of note, a previous study has 
demonstrated that deficiency in hematopoietic cell derived Il-10 in mice through transplantation 
of Il10–/– bone marrow did not affect high fat diet induced tissue inflammation and insulin 
resistance217. In that study, Il10 mRNA and protein abundances were up-regulated several-fold in 
WAT and liver. It is unclear whether the compensatory increase in Il-10 production was from 
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non-hematopoietic cells or from residual wt bone marrow-derived cells. The result seems to 
suggest that increased Il-10 levels within metabolic tissues are sufficient to maintain metabolic 
homeostasis.  
 While adipose tissue is known to produce adipokines, such as leptin, adiponectin and 
resistin, to modulate systemic glucose and lipid metabolism, it is not a major tissue for glucose 
uptake under physiological conditions. LNFPIII treatment did not affect the expression of these 
adipokines in WAT (Table 1 and data not shown). How, then, does increased WAT insulin 
sensitivity by LNFPIII lead to improvement in systemic glucose homeostasis? It has been shown 
that GTT and ITT in muscle-specific insulin receptor knockout (MIRKO) mice were 
indistinguishable from control animals, even though insulin stimulated glucose uptake was 
substantially reduced in muscle (the major site of glucose disposal)218. Subsequent studies 
attributed the normo-glycemic phenotype of MIRKO mice to a three-fold induction in glucose 
deposition to WAT219, suggesting that, at least in mice, increased glucose uptake by adipocytes 
was able to sustain glucose homeostasis. Consistent with this notion, over-expression of the 
glucose transporter Glut4 in adipose tissues improved glucose tolerance220. Recently, increased 
glucose flux in adipocytes has been shown to up-regulate fatty acid synthesis through a novel 
isoform of carbohydrate-responsive-element-binding protein (Chrebp-β, also known as 
Mlxipl)221. In addition, the expression of adipose MLXIPL and lipogenic genes positively 
correlates with insulin sensitivity in humans221-223. My data demonstrate that LNFPIII treatment 
increased WAT glucose uptake and lipogenic gene expression. Mlxipl was also induced (data 
not shown).  
While the mechanism through which fat synthesis in adipose tissues contributes to whole 
body homeostasis is not completely understood, a lipogenic product of adipocytes has been 
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linked to improved systemic metabolism224. The beneficial effect of LNFPIII could also be 
mediated by central regulation, in which reduced inflammation may lead to improved central 
insulin sensitivity that is known to regulate hepatic glucose production225,226. However, LNFPIII 
did not affect gluconeogenesis based on pyruvate tolerance tests and the expression of 
gluconeogenic genes in the liver (data not shown). Taken together, my results demonstrate a 
therapeutic potential for LNFPIII in treating components of metabolic syndrome through its 
ability to directly modulate both immune and metabolic pathways. 
 
Materials and Methods 
Animal experiments. Male C57BL/6J mice at 8–10 weeks of age (Jackson Laboratory) were 
placed on a high-fat, high-carbohydrate diet (F3282, Bio-Serv) for the duration of the 
experiments. Six weeks after high fat feeding, mice were injected (i.p.) twice per week with 25 
µg of dextran (40 kDa, vehicle) or LNFPIII conjugated with dextran (~8–10 LNFPIII/dextran). 
Experiments were reproduced in 3 independent mouse cohorts (n=5–7/treatment). Three 
additional cohorts (n=4–6/treatment) were treated with 0.9% NaCl (vehicle) or SEA dissolved in 
0.9% NaCl (25 µg/twice a week). LNFPIII and SEA were prepared as described204,227.  
Metabolic studies started 4 weeks after LNFPIII or SEA treatment and were conducted after 6hr 
fasting. Animals were sacrificed at the 6th week of treatment for serum and tissue collection. For 
rIl-10 experiments, mice were treated with PBS (vehicle) or rIl-10 (Peprotech; 1ug/every other 
day, i.p.) after 4 weeks of high fat diet. Body weight and food intake were monitored weekly. 
GTT was performed by injecting 1 g glucose per kg body weight into the peritoneum. Blood 
glucose was measured before and after injection at the time points indicated using a OneTouch 
glucose monitoring system (LifeScan). ITT was conducted similarly by injecting 1 U kg–1 body 
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weight of insulin. In vivo insulin signaling was determined by injecting 5 U kg–1 body weight of 
insulin through the portal vein. Pieces of liver, epididymal fat, and muscle were collected before 
and 10 minutes after insulin injection and rapidly stored in liquid nitrogen. Additional adipose 
tissue slices were immediately incubated with 2-[H3]deoxy-D-glucose to determine insulin 
stimulated glucose uptake ex vivo228. To estimate crown like structures, a piece of epididymal fat 
pad was divided into three sections and embedded in a single paraffin block. Sequential sagittal 
sections were collected every 20 µm for H&E staining. HOMA-IR was calculated as 
described229. Levels of insulin, phospho-Akt, total-Akt, and Il-4 were measured using ELISA-
based plates from Meso Scale Discovery. Il-10 was measured using ELISA kits (Peprotech & 
Meso Scale Discovery). The Dana-Farber/Harvard Cancer Center Research Pathology Core 
provided all histological services and preliminary assessments by a pathologist. Il10–/–(male, 
n=6/genotype/treatment, C57BL/6J background) were obtained from the Jackson Laboratory. 
Metabolic studies and treatments in these animals were similar to those in wt C57BL/6J mice. 
All animal studies were approved by the Harvard Medical Area Standing Committee on 
Animals. 
 
Immunoblotting experiments. I performed Western blot analyses using antibodies to detect the 
following proteins: p-Akt (Cell Signaling # 9271, 1:1000); t-Akt (Cell signaling # 9272, 1:1000); 
Irs2 (Santa Cruz # sc-8299, 1:500); C/ebp-α (Santa Cruz # sc-61, 1:500); actin (Cell Signaling # 
4970, Clone 13E5, 1:1000); tubulin (Cell Signaling # 2128, Clone 9F3, 1:1000).  
 
Primary cells, adipocyte differentiation and functional assays. Bone marrow-derived 
macrophages were differentiated in L929 conditioned media as previously described124.  
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Dendritic cells were differentiated in the presence of macrophage colony-stimulating factor (3 ng 
mL–1) and Il-4 (5 ng mL–1). Cells were treated with dextran (control) or LNFPIII overnight. 
Following treatment, cells were washed and cultured in DMEM alone. Media was collected 8 
hours later and 10% FBS was added, which constituted the conditioned medium. For M2 
skewing experiments, macrophages were treated with dextran, LNFPIII or Il-4 overnight. Where 
indicated, cells were pretreated for 1 hour with PD98059 (10 µM, Cell Signaling) prior to 
treatments. PD98059 is an MEK1 (also called MAPKK or Erk kinase) inhibitor used to block 
Erk activation. 3T3L1 cells were differentiated as previously described in a cocktail containing 
insulin, isobutylmethylxanthine, and dexamethasone230. For differentiation experiments, 3T3-L1 
cells were given various treatments indicated together with the differentiation cocktail. At day 2, 
the cocktail was removed and differentiation continued in the presence of the treatment and 
insulin. Triglyceride analysis was performed after 6d of differentiation. Cellular lipids were 
extracted with a 2:1 (v/v) chloroform:methanol solution. For insulin signaling experiments, fully 
differentiated 3T3-L1 adipocytes (at day 6) were given the indicated treatments for 48 hr without 
insulin. Cells were washed, serum starved for 2 hr and stimulated with insulin (100 nM) for 60 
min. Glucose uptake was performed using 2-[H3]deoxy-D-glucose with a 20 min insulin pre-
stimulation. Cellular radioactivity was determined and normalized to protein content.  
 
Expression analyses. For gene expression analyses, relative expression levels were determined 
by SYBR green-based real-time quantitative PCR (q-PCR) reactions. 36B4 levels were used for 
normalization. For Western blot analyses, tissue and cell lysates were prepared in the presence of 
protease and phosphatase inhibitors.  
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Statistical analyses. Statistical analyses comparing two parameters (between treatments or 
genotypes) in cell-based work were conducted using the two-tailed Student’s t test. Two 
parameters analyses for samples from in vivo studies (non-gaussian distribution) were 
determined using the Mann-Whitney test (Figs. 8c, 8g, 9a–d, 10e, Supplementary Figs. 1d, 1g, 
2b–c, 3a, 3b, 3f–h, and Tables 1–4). Statistics for multi-parameter analyses was determined by 
One-Way ANOVA followed by Bonferroni posthoc tests (Figs. 8a, 10a–c, and Supplementary 
Figs. 1a). Two-way ANOVA was used to determine statistical significance for GTT and ITT 
(Figs. 8d–e, 10d and Supplementary Figs. 1e–f, 3c–e). Values are presented as mean ± s.e.m. For 
in vitro assays, the mean and s.e.m. were determined from 3–4 biological replicates for one 
representative experiment. Experiments were repeated at least three times. P<0.05 was 
considered significant.  
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CHAPTER 3 
LNFPIII improves HFD-induced hepatic fat accumulation and dysfunction 
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Introduction  
 The liver is a major target of metabolic dysregulation. While insulin resistance is the best 
documented pathology associated with metabolic syndrome, non-alcoholic fatty liver disease 
(NAFLD) plays a significant role in the morbidity and mortality of obese patients. NAFLD is 
characterized as a spectrum of histological changes from hepatocyte lipid accumulation without 
concomitant inflammation to steatohepatitis associated with inflammation, fibrosis, and 
cirrhosis231. While inflammatory changes, with an immune cell component, are thought to lead to 
the onset of NAFLD in many obese patients, the mechanisms that determine the extent of liver 
damage are questionable. Some researchers suggest a two hit hypothesis; once inflammatory 
signals make the hepatocytes susceptible, a second oxidative stress leads to the transformation of 
the hepatocytes to fibrotic and cancerous232. Patients with NAFLD are prescribed interventions 
aimed at reducing lipid burden and inflammation233. However, there is currently no proven 
treatment for NAFLD.  
Several nuclear receptors are known to control glucose and lipid metabolism in the liver. 
Peroxisome proliferator-activated receptor (Ppar, also known as Nr1c1)-α regulates β-oxidation 
and gluconeogenesis in the fasted state128. The liver X receptor (Lxr, also known as Nr1h3)–α –
farnesoid X receptor (Fxr, also known as Nr0b2)-α pathway controls cholesterol and bile acid 
metabolism. Fxrα has also been shown to suppress hepatic lipogenesis in small heterodimer 
partner (Shp)-dependant and –independent mechanisms through suppression of sterol regulatory 
element binding protein (Srebp)-1c 234. Fxra–/– mice have increased hepatic lipid storage with 
peripheral insulin resistance, suggesting a role for Fxrα as a potential therapeutic target for 
NAFLD235. In Chapter 3, I show that LNFPIII directly regulates the lipogenic program in 
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hepatocytes and prevents obesity-induced hepatic steatosis through an unexpected link to the 
nuclear receptor Fxrα.  
Results 
LNFPIII protects against diet-induced hepatic steatosis   
In addition to improving WAT function, histological and triglyceride content analyses 
showed a strong protective effect of LNFPIII against HFD-induced hepatic lipid accumulation 
(Fig. 11a). Furthermore, overall liver function, determined by circulating levels of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), was significantly improved (Fig. 
11b). In line with reduced hepatic steatosis, lipogenic genes, including fatty acid synthase (Fas), 
acetyl-CoA carboxylase1/2 (Acc1/2), stearoyl-CoA desaturase 1 (Scd1) and sterol regulatory 
element-binding protein 1c (Srebp1c, also known as Srebf1), were suppressed in LNFPIII-treated 
livers (Fig. 11c).  
Srebp-1c is a master lipogenic transcription factor whose expression and transcriptional 
activity are controlled by a network of nuclear receptor signaling pathways, notably, the positive 
regulator Lxrα (NR1H3)236,237 and negative regulators Fxrα (NR1H4) and its target Shp 
(NR0B2)234. The Fxrα gene consists of two major 5’ regulatory regions, with the upstream and 
downstream promoters driving the expression of Fxr-α1/α2 and Fxr-α3/α4 isoforms, 
respectively (Fig. 13a)238. The only difference between Fxr-α1/α2 (or Fxr-α3/α4) is a 4 amino 
acid insertion in Fxr-α1 (or Fxr-α3). I found that expression of Fxr-α3/α4 isoforms as well as 
several known Fxr target genes238, including Shp, organic anion-transporting polypeptides (Oatp, 
also known as Slco1a1), phospholipid transfer protein (Pltp) and bile salt efflux pump (Bsep, 
also known as Abcb11), were up-regulated in livers of LNFPIII treated mice, compared to 
vehicle treated controls (Fig. 11c). Lxrα expression remained unchanged. Similar effects were 
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Figure 11 LNFPIII protects against high fat diet induced hepatic steatosis. (a) Liver histology and triglyceride 
content analyses to determine hepatic fat accumulation in vehicle and LNFPIII treated mice. Scale bar = 100 µm. (b) 
Circulating AST and ALT concentrations to assess liver function. (c) Gene expression analyses in livers from 
vehicle or LNFPIII treated mice (n = 5) by real-time q-PCR. Values are expressed as means ± s.e.m. Metabolic 
studies were reproduced in three mouse cohorts (n = 5–7 per treatment). Histology was examined in one and lipid 
and expression analyses were examined in three of the three cohorts. *P < 0.05 (LNFPIII versus vehicle control). 
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obtained with SEA treatment, except that SEA up-regulated both Fxr-α1/α2 and Fxr-α3/α4 
(Supplementary Fig. 4a–d). Metabolic gene expression in muscle was largely unaffected by 
LNFPIII or SEA (Supplementary Fig. 4e and data not shown). These results indicate that 
LNFPIII prevents ectopic fat accumulation in the liver and regulates the expression of 
transcriptional factors critical for de novo lipogenesis. 
To assess the role of LNFPIII or LNFPIII primed macrophages in hepatic lipid 
homeostasis, de novo lipogenic assays were conducted in isolated primary hepatocytes. LNFPIII, 
but not conditioned medium from LNFPIII-treated macrophages, suppressed lipogenesis and 
increased fatty acid β-oxidation compared to vehicle treatment (Fig. 12a). LNFPIII also induced 
expression of Fxr-α3/α4 and Shp as well as suppressed Srebp1c and Acc1 (Fig. 12b). As 
LNFPIII did not affect β-oxidation gene expression (Fig. 11c and 12b), the increased fat burning 
was likely secondary to decreased fatty acid synthesis. These results suggest that unlike in WAT, 
the LNFPIII effect in the liver was not mediated by Il-10. Consistent with this notion, rIl-10 
treatment did not affect hepatic de novo lipogenesis in vitro or in vivo (Supplementary Fig. 5a–
c) and the protective effect of LNFPIII was preserved in Il10–/– liver (Supplementary Fig 5d–e). 
 
LNFPIII suppresses hepatic de novo lipogenesis through FXR 
The up-regulation of the Fxrα-dependent transcription program by LNFPIII in the liver 
suggested that LNFPIII may induce Fxrα to inhibit fat synthesis. In fact, in hepatocytes with 
Fxrα gene ablation or Erk inhibition by PD98059, LNFPIII was unable to inhibit de novo 
lipogenesis and increase fat oxidation (Fig. 12c). Furthermore, the ability of LNFPIII to reduce 
hepatic triglyceride accumulation, improve liver function and suppress lipogenic gene expression 
was lost in Fxra–/– mice (Fig. 12d–e and Supplementary Fig. 5f), while the insulin sensitizing  
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Figure 12 LNFPIII suppresses lipid synthesis through Fxr-α. (a) De novo lipogenesis (left panel) and fatty acid β-
oxidation (right panel) assays in primary hepatocytes treated with vehicle, LNFPIII (20 µg ml–1) or CM from 
LNFPIII primed wt macrophages. (b) Gene expression in hepatocytes treated with vehicle or LNFPIII determined 
by real-time q-PCR. (c) Lipogenic (left panel) and β-oxidation (right panel) assays in hepatocytes isolated from wild 
type (wt) or Fxrα–/– mice ± LNFPIII ± PD98059. (d and e) Hepatic triglyceride content and serum AST and ALT 
concentrations in wt and Fxrα–/–mice ± LNFPIII treatment (n = 6). Values are expressed as means ± s.e.m. For in 
vitro assays, the mean and s.e.m. were determined from 3–4 biological replicates for a representative experiment. 
Experiments were repeated 3 times. Studies for Fxrα–/– and control mice were conducted in one cohort (n = 6 per 
treatment per genotype). *P < 0.05 (LNFPIII versus vehicle control).  
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activity of LNFPIII was unaffected (Supplementary Fig. 5g–5i and Table 4). Together, the 
results suggest LNFPIII inhibits hepatic lipogenesis in a Fxrα-dependent manner.  
I next sought to determine if Fxrα is a molecular target of LNFPIII. As mentioned earlier, 
both human and mouse Fxrα contain two major promoters (Fig. 13a). Sequence comparison 
analyses revealed that the 5’ regulatory sequences were highly conserved between mouse, rat and 
human Fxrα genes (Supplementary Fig. 6a). The activities of reporters driven by upstream 
(promoter 1) or downstream (promoter 2) regulatory regions were examined in HepG2 cells 
(human hepatoma cells). In accordance with the regulation of Fxrα in the liver or isolated 
hepatocytes, LNFPIII activated Fxrα promoter 2, while SEA induced the activity of both 
promoters (Fig. 13a). In vivo, Fxrα protein levels were higher in liver lysates from LNFPIII 
treated mice (Fig. 13a). A minimal LNFPIII responsive region (approximately 130 bp upstream 
of the transcriptional start site) was defined through serial deletion of promoter 2, which 
contained consensus binding sites for C/EBP and AP1 (Supplementary Fig. 6a). Site directed 
mutagenesis experiments further identified two overlapping AP1 sites (located between –57 and 
–47 bp) that were required for the induction of Fxrα promoter 2 by LNFPIII (Fig. 13b and 
Supplemental Fig. 6b). Similarly, inhibition of Erk activation, which is upstream of AP1, by 
PD98059 abolished LNFPIII induced activity of Fxrα promoter 2. In concert, LNFPIII treatment 
increased levels of phospho-Erk and total Erk in the liver (Fig. 13c) and hepatocytes (Fig. 13d). 
Similar results were observed in SEA treated liver cells (Supplementary Fig. 6c–
d).Collectively, these findings suggest that LNFPIII regulates hepatic lipogenesis through the 
Erk-AP1-Fxrα axis. 
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Figure 13 Induction of Fxrα activity by LNFPIII is mediated by Erk-Ap1 signaling. (a) Top panel: genomic 
structure showing alternative promoter usage by human FXR-α1/α2 (promoter 1) and FXR-α3/α4 (promoter 2). 
Bottom left: Relative activities (RLU) of luciferase reporters driven by human FXRα promoter 1 (~2 kb) or human 
FXRα promoter 2 (~0.13 kb) in HepG2 cells ± LNFPIII (20 µg ml–1) or SEA (2 µg ml–1). Bottom right: Western 
blotting showing Fxrα protein levels in livers from vehicle or LNFPIII treated mice. (b) Top panel: diagram 
demonstrating FXRα promoter 2 (p2–0.13kb) or mutant (p2–0.13kb–M) reporter constructs. The two overlapping 
AP1 binding sites and the mutation are shown. Bottom panel: Relative luciferase activities of p2–0.13kb and p2–
0.13kb–M ± LNFPIII ± PD98059 (c) Erk phosphorylation (p-Erk) in livers of vehicle and LNFPIII treated mice. 
Bottom panel: Quantification of the Western signal. (d) Western blot analyses showing Erk phosphorylation in 
hepatocytes ± LNFPIII ± PD98059 (representative samples from three experiments each with three biological 
replicates). Bottom panel: Quantification of the Western signal. Values are expressed as means ± s.e.m. For in vitro 
assays, the mean and s.e.m. were determined from 3–4 biological replicates from one of three repeats. Hepatic p-Erk 
was determined from one of three metabolic study cohorts (n = 5, showing 3 representative samples). *P < 0.05 
(LNFPIII or SEA versus vehicle control). (e) Model for direct and indirect regulation of metabolic pathways by 
LNFPIII. DC: dendritic cells. 
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                         Table 4. Metabolic parameters of Fxra–/– mice treated with LNFPIII 
 
 
Serum samples were collected after 6 hr fasting. *P<0.05.    
Values displayed as mean ± s.e.m.  n=6/group 
 
 
 
 
 
 
Treatment Vehicle LNFPIII 
Body weight (g) 40.73 ± 3.23 36.33 ± 3.54 
WAT/body weight 0.029 ± 0.003 0.041 ± 0.003 
Liver/body weight 0.046 ± 0.004 0.053 ± 0.011 
Triglyceride (mg dL–1) 46.12 ± 5.22 44.11 ± 4.90 
Free fatty acid (mmol L–1) 0.40 ± 0.02 0.49 ± 0.03 
Cholesterol  (mg dL–1) 303.18 ± 27.10 315.47 ± 8.16 
Glucose (mg dL–1) 175 ± 4.38 150 ± 18.78 
Insulin (ng mL–1) 0.450 ± 0.025 0.198 ± 0.026* 
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Discussion 
In addition to the LNFPIII-IL-10 insulin-sensitizing axis in WAT described in Chapter 2, 
here I show a role for LNFPIII in improving hepatic function. In the liver, LNFPIII up-regulates 
bile acid sensing nuclear receptor FXRα and its downstream targets. Activated Fxrα signaling 
suppresses lipogenesis and protects against hepatic steatosis.  
After entering the body, S. mansoni settles in the hepatic portal system where male and 
female worms mate and produce eggs191. Egg deposition in the liver is critical for induction of a 
systemic TH2 response191. It is therefore not surprising that the liver is also a target of LNFPIII. 
At first glance, it seems unexpected that LNFPIII directly controls Fxrα signaling to regulate 
hepatic lipid metabolism. Fxrα senses endogenous bile acids and controls bile acid homeostasis 
by inhibiting production while increasing the recycling of bile acids in the enterohepatic 
system239. Fxrα activation also suppresses de novo lipogenesis through Shp-mediated inhibition 
of Srebp-1c in the liver234. Interestingly, S. mansoni is incapable of de novo synthesis of fatty 
acids and sterols but is able to synthesize complex lipids from precursors acquired from the 
host240. In addition, it has been shown that bile acids increase the number of deposited parasite 
eggs241. Therefore, the induction of Fxrα by LNFPIII could be the host’s response to limit fatty 
acids and bile acids available to the worm. In contrast, bile acids facilitate lipid absorption in the 
intestine. Increased bile flow via Fxrα may help schistosomes to extract lipids from the digestive 
system of the host. Additionally, the induction of Fxrα could serve as an anti-inflammatory 
mechanism in the liver as Fxrα is known to trans-repress Nf-κb activity242. Although future 
studies are needed to test these potential mechanisms, these data demonstrate that LNFPIII 
improves overall liver function through targeting the metabolic program.  
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The signal transduction pathway of LNFPIII has not been fully characterized. In dendritic 
cells, LNFPIII is recognized by multiple CLRs, including DC-SIGN (also known as Cd209), 
Mgl1 and mannose receptor. In addition, Erk is proposed to be a downstream effector of 
LNFPIII205,243. Erk/AP1 has been shown to regulate Il10 expression211. Consistent with this 
observation, the ability of LNFPIII to induce Il-10 production in the macrophage was blocked by 
Erk inhibition. Notably, I find that primary hepatocytes also express CLRs, such as DC-SIGN 
(data not shown) and LNFPIII is able to activate Erk in the liver, which mediates Fxrα 
transcriptional regulation and the subsequent suppression of lipogenesis. The gene products of 
the two promoters (Fxr-α1/α2 versus Fxr-α3/α4) differ by several amino acids located at the N-
terminus. Functional differences between isoforms have not been reported238. My data suggests 
that the induction of Fxr-α3/α4 by LNFPIII is sufficient to suppress lipogenesis. While LNFPIII 
only activates the downstream Fxrα promoter, SEA induces the activities of both promoters. 
This is not unexpected, since SEA is known to contain multiple bioactive glycans that could 
signal through different pathways243. Together, my data show that helminths may utilize the Erk-
AP1 signaling pathway to modulate host metabolism and immune responses (Fig. 6e). My study 
suggests that the M2-like, anti-inflammatory activity of LNFPIII, which is likely the product of 
helminth’s survival strategy, may be used to treat metabolic disorders, such as insulin resistance 
and nonalcoholic fatty liver diseases. 
 
Materials and Methods 
All methods are the same as in Chapter 2. Additional methods utilized in Chapter 3 are detailed 
below. 
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Animal experiments. Serum and tissue lipids, ALT and AST were measured using commercial 
kits as described previously244. Fxra–/– mice (male, n=6/genotype/treatment, C57BL/6J 
background) were obtained from the Jackson Laboratory. Metabolic studies and treatments in 
these animals were similar to those in wt C57BL/6J mice. All animal studies were approved by 
the Harvard Medical Area Standing Committee on Animals. 
 
Immunoblotting experiments. I performed Western blot analyses using antibodies to detect the 
following proteins: Fxrα (R&D systems, # PP-A9033A-00, Clone A9033A, 1:500 and Santa 
Cruz Biotechnology # sc-1204, 1:500); p-Erk (Cell signaling # 9101, 1:1000); t-Erk (Cell 
signaling # 4695, 1:1000). 
 
Primary cells and functional assays. Primary hepatocytes were isolated as previously 
described244,245. Hepatocytes were allowed to attach overnight in William’s E, 5% FBS, followed 
by treatments for 24 hr. For de novo lipogenesis, cells were labeled with 14C-acetate and lipids 
were extracted with a 2:1 (v/v) chloroform:methanol mixture 6 hrs later. β-oxidation was 
conducted as described previously245. For LNFPIII signaling in hepatocytes, attached 
hepatocytes were pretreated with Erk inhibitor where indicated for 1 hr followed by a 30 min 
incubation with dextran or LNFPIII.  
 
Expression analyses. The four Fxrα (Nr1h4) isoforms were based on previous reports, which 
were originally designated as Fxr-α1/α2 and Fxr-β1/β2238,246. The latter were renamed as Fxr-
α3/α4 to avoid confusion with the rodent Fxrβ (Nr1h5)238. For reporter assays, the upstream 
promoter 1 and downstream promoter 2 regions of human FXRα gene were cloned into the 
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pGL3-basic luciferase reporter construct and transfected into HepG2 cells in a 96-well format. A 
β-galactosidase reporter construct was used as a transfection control.  
 
Statistical analyses. Statistical analyses comparing two parameters (between treatments or 
genotypes) in cell-based work were conducted using the two-tailed Student’s t test. Two 
parameters analyses for samples from in vivo studies (non-gaussian distribution) were 
determined using the Mann-Whitney test (11a–c, 12d–e, 13c, Supplementary Figs. 4a–d, 5d–e, 5i 
and Tables 1–4). Statistics for multi-parameter analyses was determined by One-Way ANOVA 
followed by Bonferroni posthoc tests (Figs. 12a, 12c, 13a, 13d and Supplementary Figs. 5a, 6c–
d). Two-way ANOVA was used to determine statistical significance for GTT and ITT 
(Supplementary Figs. 5f–g). Values are presented as mean ± s.e.m. For in vitro assays, the mean 
and s.e.m. were determined from 3–4 biological replicates for one representative experiment. 
Experiments were repeated at least three times. P<0.05 was considered significant.  
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CHAPTER 4 
A role for PPARδ  and PPARγ  in macrophage bacterial killing 
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Introduction 
It is well established that patients with altered metabolic function such as those with type 
II diabetes mellitus or elderly people, are more likely to die from bacterial or fungal 
infections16,247,248. Respiratory infections are the fifth leading cause of disease in people aged 65 
and older249. Vaccines have also proven less effective in these populations250. To date, several 
immunological biomarkers have been associated with the increased risk of infections in these 
susceptible populations. However, the significance of these immunological changes is poorly 
understood. Simultaneously, these same populations exhibit a systemically decreased metabolic 
rate, increased fat accumulation, and increased oxidative stress251. Metabolic changes have also 
been observed in the macrophage252. Functionally, myeloid-derived cells from elderly patients 
and patients with metabolic syndrome have decreased bactericidal capacity and respiratory 
burst253-257. These processes are critically dependent on gross metabolic state, implicating 
macrophage metabolic dysregulation in the susceptibility to infection. Identifying signaling 
nodes critical for regulating metabolic function in the macrophage can provide a novel 
mechanism to improve host bactericidal activity in susceptible populations.  
When activated by pathogens or proinflammatory cytokines, macrophages activate 
signaling cascades that lead to changes in energy producing processes within the cell, including 
an increased dependance on anaerobic respiration and increased flux through the pentose 
phosphate pathway (PPP)116,159. High-energy molecules, such as adenosine triphosphate (ATP) 
and nicotinamide adenine dinucleotide phosphate (NAD(P)H), produced in these processes are 
crucial for the substrate driven activities of enzymes involved in various processes such as 
phagocytosis, movement, and cytokine production. In contrast, anti-inflammatory macrophages 
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display a distinct metabolic phenotype characterized by the reliance on oxidative metabolism for 
sustained energy for repair and resolution163.  
Peroxisome proliferator-activated receptors (PPARs) are ligand activated transcription 
factors critical for maintaining metabolic homeostasis by sensing extracellular nutrients and 
modulating intracellular metabolism. The Ppar family of receptors consists of Pparα (Nr1c1), 
Pparδ (Nr1c2) and Pparγ (Nr1c3) and is best known for sensing fatty acids and regulating 
metabolic processes128. In the macrophage, Pparδ and Pparγ regulate oxidative metabolism and 
anti-inflammatory macrophage functions, such as apoptotic cell clearance124,134,258. Given the 
established role of PPARs in cellular metabolism, immune cell function and organelle regulation, 
I hypothesized that Pparδ and Pparγ are critical for coordinating metabolic and immune 
responses for efficient bacterial killing. Using the gram-positive bacteria Streptococcus 
pneumoniae (S.pneumoniae), I show here that Pparδ regulates phagosomal ROS production and 
subsequent bacterial killing in the macrophage. My data also suggest that Pparγ deficient 
macrophages are unable to efficiently kill bacteria. Pharmacological interventions that increase 
Pparδ activity improve the survival of mice infected with S.pneumoniae, suggesting that 
modulating host metabolic sensing pathways can have positive outcomes in various patient 
populations that have age- or metabolically-weakened immune systems.  
Results 
Lack of Pparδ  in the macrophage inhibits bacterial killing 
Given the importance of metabolic pathways in bacterial killing, the role of Pparδ as a 
lipid sensing nuclear receptor makes it an interesting candidate to integrate metabolic and 
immune signals and regulate bacterial killing. In fact, macrophages treated with S.pneumoniae 
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exhibited increased expression of Pparδ and its known target gene, solute carrier family 25, 
member 20 (Slc25a20) (Supplementary Fig. 7). To elucidate a critical role for Pparδ during 
bacterial infection, I treated fully differentiated PparδKO and wt bone marrow derived 
macrophages with S.pneumoniae to determine killing efficiency in a gentamicin-protection 
assay. Macrophages lacking Pparδ had approximately two times as many bacteria remaining 
after two hours compared to wt macrophages (Fig 14a). Because of the known role of Pparδ as a 
metabolic regulator and the critical function of metabolites in efficient bacterial killing128,164,166, I 
investigated various metabolic pathways that may be dysregulated. Expression of genes in the 
pentose phosphate pathway [glucose-6-phosphate dehydrogenase (G6pdh) and phosphogluconate 
dehydrogenase (Pgd)] and the mitochondrial β-oxidation pathway [cytochrome C oxidase (Cox)-
2 and Cox3, ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (ATP5o), and 
cytochrome B (Cytb)] was unchanged in wt macrophages compared to knockout cells. Lactate 
dehydrogenase b (Ldhb), the enzyme critical for the macrophage switch to anaerobic respiration 
during bacterial killing, was also unchanged during infection. (Supplementary Fig 8a). 
Functional assays revealed an inability of PparδKO macrophages to increase glucose uptake 
during bacterial infection (Supplementary Fig. 8b). However, this did not translate into a defect 
in mitochondrial number, lactate production or ATP levels (Supplementary Fig. 8c-e). 
Therefore, I turned my attention to steps critical for successful phagocytosis (Fig. 4).  
I found no difference in uptake or binding of bacteria by the macrophage in wt and 
PparδKO macrophages (Fig. 14a). Rate of phagocytosis and number of phagosomes generated 
by bacterial uptake was unaffected by reduced Pparδ abundances (Fig. 14b-c). There was also no 
defect observed in fusion of the phagosome to the lysosome (data not shown). Once the  
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Figure 14: PPARδ promotes efficient bacterial killing. (a) In vitro killing assay in wt and PPARδKO macrophages. 
Primary bone marrow derived macrophages were infected with S.pneumoniae (10 bacteria: 1 macrophage) to 
determine intracellular killing in vitro. (b) Phagocytosis assay in wt and PPARδKO macrophages. Macrophages 
were infected with heat-killed S.pneumoniae labelled with Alexa Fluor 647 (25 bacteria: 1 macrophage) for the 
indicated times and fluorescence was determined by FACS. (c) Number of phagosomes found in heat-killed Alexa 
Fluor 647: S.pneumoniae infected wt and PPARδKO macrophages 60 minutes after infection. Phagosome number 
was determined by dividing the mean fluorescence intensity (MFI) of the macrophage (with ingested bacteria) by 
the MFI of a single bacterium. (d and e) Phagosome acidification is not defective in PPARδKO macrophages. (d) 
Acidification was determined by infecting macrophages with heat killed S.pneumoniae dually labeled with FITC 
(pH sensitive) and Alexa Fluor 647 (pH insensitive). Fluorescence was quantified by FACS and pH was caluculated 
from the ratio of Alexa Fluor 647: FITC in the unknown samples and that of a known standard curve. (e) 
Phagosomal pH was determined using pHrodo (Invitrogen). (f) ROS production is blunted in PPARδKO 
macrophages. FcOxyburst was used to track the phagosomal oxidative burst by FACS analysis. 
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phagosome is properly formed, critical enzyme complexes help to acidify the phagosome and   
produce ROS to help degrade bacteria259. In PparδKO macrophages, both phagosomal 
acidification and ROS production were reduced compared to wt macrophages. (Fig. 14d–f). 
Taken together, my data reveal a novel role for Pparδ in bacterial killing possibly through 
changes in phagosomal regulation.  
 
PPARδ  regulates expression of phagosomal genes  
To elucidate a mechanism for Pparδ regulation of phagosomal ROS production, gene 
expression of phagosomal genes was analyzed in stably transformed wt and PparδKO 
macrophages prior to and during S.pneumoniae infection. Gene expression revealed that some 
genes from the NADPH oxidase family (Nox2, Noxo1, and Noxa1) were all significantly 
decreased. Interestingly some of the associated proteins, such as p47phox and p22phox were 
upregulated in knockout cells compared to wt cells. No difference was observed in gene 
expression of components of the vacuolar ATPase complex (Fig. 15a). The data suggest a role 
for Pparδ in NADPH oxidase regulation.  
To determine whether members of the NADPH complex are direct targets of Pparδ, I first 
studied Pparδ activity during infection with S.pneumoniae by assessing ligand binding activity of 
Pparδ. When infected with S.pneumoniae, macrophages that contained a Gal4-Pparδ ligand 
binding domain fusion contruct had significantly higher luciferase activity than cells containing a 
Gal4 control plasmid (Fig. 15b). I then generated luciferase constructs with promoters 2kb 
upstream of the transcription start site of both Noxo1 and Nox2. I observed that Pparδ ligand,  
GW501516, was able to increase luciferase activity of the 2kb Noxo1 promoter, but not the 2kb  
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Figure 15: Pparδ regulates phagosome function by regulating Noxo1 transcription.  (a) Expression of NADPH 
associated proteins Noxo1 and Noxa1 were reduced in PparδKO macrophages. Expression of genes that comprise 
the vacuolar ATPase and the NADPH oxidase complex were analyzed. (b) S.pneumoniae increases activity of the 
ligand binding domain (LBD) of Pparδ. Macrophages were transfected with Gal4-Pparδ LBD along with a Gal4 
responsive luciferase construct. After transfection, macrophages were infected with S.pneumoniae for 12 hours. (c) 
Pparδ ligand, GW501516, increases luciferase activity of the Noxo1 promoter, but not the Nox2 promoter. 2kb of the 
Noxo1 or Nox2 promoter upstream of the transcriptional start site was cloned into a plasmid upstream of the 
luciferase gene. Transfection was done in Raw264.7 macrophages. (d) Pparδ ligand is unable to increase Noxo1 
transcription in the absence of Pparδ. Transfection was done in stably transformed wt and PparδKO macrophages.  
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Nox2 promoter (Fig. 15c). This effect was lost in cells lacking Pparδ (Fig. 15d). Together my 
data suggest that during bacterial infection Pparδ regulates Noxo1 transcription.  
 
Pparδ  promotes bacterial killing in vivo   
To understand if Pparδ regulation of phagosomal ROS production contributes to bacterial 
killing in vivo, I measured ROS production in isolated alveolar macrophages from wt and 
macrophage specific Pparδ knockout mice. Similar to my in vitro data, Pparδ knockout alveolar 
macrophages were unable to produce phagosomal ROS (Fig. 16a). Oral gavage with GW501516 
for three days prior to alveolar macrophage isolation increased ROS production in wt 
macrophages, but not in Pparδ knockout macrophages (Fig. 16a). To understand if defects in 
phagosomal ROS resulted in an inability to kill bacteria in vivo, myeloid specific Pparδ knockout 
mice (PparδLysM; Pparδfl/fl used as wt controls) were infected intranasally with S.pneumoniae and 
surviving bacterial burden was measured from bronchoalveolar lavage fluid (Balf) 24 hours post 
infection. (Fig. 16b). Circulating cell numbers were not different in infected wt or PparδLysM 
mice, suggesting that PparδLysM mice have no defect in recruitment of cells to the site of 
infection. Differential cell counts of Balf indicated that the number of neutrophils was 
significantly higher in knockout mice compared to wt mice, in agreement with the increase in 
bacterial counts in the lung (Supplementary Fig. 9a-c). No differences were observed in Tnfα, 
while Il-6 concentrations were significantly higher in Balf of knockout mice compared to wt 
mice (Supplementary Fig. 9d). Gene expression from infected alveolar macrophages 24 post 
infection indicated a defect in both Noxo1 and Noxa1 expression, similar to the results observed 
in vitro (Fig. 16c). The results indicate a critical role for Pparδ in regulating phagosome function 
and efficient bacterial killing in vivo. 
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Figure 16: Alveolar macrophages from PPARδlysM mice have a defect in ROS production and are unable to kill 
bacteria. (a) Three day in vivo treatment of PPARδ ligand, GW501516, is able to increase ROS production in 
alveolar macrophages from wt mice. This effect is lost in knockout mice. Mice were gavaged with 2mg/kg/day of 
GW501516. Alveolar macrophages were isolated and ROS was determined with FxOxyburst. (b) 24 hour in vivo 
killing assay. Wt and PPARδlysM mice were infected intranasally with S.pneumoniae for 24hrs and percent bacterial 
survival was determined. (c) Gene expression from lavage fluid from mice 24 hours after infection with 
S.pneumoniae.  
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PPARδ  ligand, GW501516, improves macrophage bacterial killing 
I next wanted to investigate whether ligand treatment in vivo could improve bacterial 
killing. Mice were gavaged with GW501516 for 3 days (2 mg kg-1 per day) and infected with 
S.pneumoniae for 24 hours. Surviving bacteria was determined from Balf. There were less 
bacteria remaining in the lungs of ligand treated mice compared to vehicle treated mice (Fig. 
17a). Gene expression analyses of Balf cells showed an increase in expression of Pparδ and its 
target gene Slc25a20, confirming ligand efficacy. The expression of Noxo1 was also increased 
(Fig. 17b). Defective bacterial killing in PparδLysM mice was associated with earlier death 
relative to wt mice. Ligand treatment did not improve survival in knockout mice. However, with 
ligand treatment, no death was observed in wt mice (Fig. 17c). Taken together, my data suggest 
that Pparδ regulates phagosomal ROS production and Noxo1 transcription. Ligands that target 
Pparδ improve bacterial killing suggesting a role for activators that target metabolic sensors in 
the treatment of bacterial infections.  
Epidemiological data has shown that neonates, elderly people (65+), and people with type 
2 diabetes are more susceptible to bacterial infections16,260,261.  In neonatal and elderly mice, 
expression of Slc25a20 and Noxo1 was significantly decreased in unstimulated macrophages 
(Fig. 17d-e). This decrease in gene expression correlated with a decrease in ROS production ex 
vivo (Fig. 17f). Three-day ligand treatment in three-year-old mice was associated with a 50% 
increase in ROS production, although ligand was unable to completely rescue ROS production to 
the levels of two-month-old mice. Together, I show here that ligand treatment can be an effective 
method to increase ROS production in older mice that have defects in phagosomal gene  
expression.  
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Figure 17: Ligand activation of PPARδ improves bacterial killing in vivo. (a) Oral gavage of GW501516 improves 
bacterial killing in vivo. 24 hours post infection, lavage fluid was isolated and analyzed for live bacterial forming 
colonies. (b) Gene expression analyses on lavage fluid indicate that ligand activation of PPARδ increases expression 
of known target gene (Slc25a) and phagosomal markers (NOX2 and NOXO1). Mice were gavaged with GW501516 
for three days prior to intranasal infection. (c) Survival curves were determined for wt and macrophage specific 
PPARδ knockout mice with and without ligand treatment. Wt and PPARδlysM mice were gavaged with GW501516 
orally for 3 days prior to and throughout the course of infection. On day 0, mice were infected with 105 CFU of 
S.pneumoniae and were monitored daily for signs of death and changes in body weight. (d) Gene expression of 
alveolar macrophages from uninfected 3wk or 8wk old mice. (e) Gene expression of alveolar macrophages from 
uninfected 2mos or 36mos old mice. (f) Three day in vivo treatment of PPARδ ligand, GW501516, is able to 
increase ROS production in alveolar macrophages from both young and old wt mice. Mice were gavaged with 
2mg/kg/day of GW501516. Alveolar macrophages were isolated and ROS was determined with FxOxyburst.  
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Pparγ  also influences macrophage bactericidal activity 
The inability of Pparδ ligand to completely rescue the defects in phagosomal ROS production in 
three-year-old mice implicated another receptor in regulation of ROS production. Iturned my 
attention to the role of Pparγ in the same processes. During a bacterial infection, Pparδ and Pparγ 
become transcriptionally activated (Fig. 18a). However, this regulation appears to be temporal 
with maximal Pparg expression appearing at 1 hour post infection followed by Ppard expression 
peaking at about 9 hours post infection (Fig. 18a). Additionally, Pparγ ligand activation with 
troglitazone, led to increases in expression of genes critical for anaerobic respiration and lactate 
production (Ldhb) and the pentose phosphate pathway (Pgd). Additionally, genes involved in 
phagosomal ROS production, also shown to be regulated by Pparδ, were increased by 
troglitazone treatment (Fig. 18b). However, analysis of uninfected alveolar macrophages from 
PparδLysM or PparγLysM mice suggests a differential role for both receptors (Fig. 18c). In alveolar 
macrophages from PparδLysM mice, Ppard expression is reduced about 95% while there are no 
differences observed in Pparγ expression compared to wt mice. In these cells, I only observe 
differences in the expression of phagosomal genes. However, in PparγLysM mice, expression of 
both Ppard and Pparg was reduced about 50% compared to wt macrophages. Additionally, 
expression of both phagosomal and metabolic genes was reduced significantly, with the 
reduction in phagosomal gene expression presumably due to a decrease in Ppard expression 
(Fig. 18d). Preliminary data suggest a role for Pparγ in regulating the metabolic switch from 
aerobic to anaerobic respiration, thereby producing high-energy molecules such at ATP and  
NADPH that are critical for bacterial killing. 
 To access the role of Pparγ in bacterial killing, I performed in vitro and in vivo bacterial  
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Figure 18: PPARγ also contributes to macrophage bactericidal activity. (a) PPARδ and PPARγ expression is 
increased during macrophage bacterial infection. BMDM were treated with S.pneumoniae for the indicated times. 
(b) Gene expression analysis of PPARγ overexpressing macrophages treated with or without ligand. Troglitazone is 
able to increase expression of metabolic and phagosomal genes. (c and d) Gene expression of alveolar macrophages 
from uninfected PPARδlysM or  PPARγlysM  mice. (e) In vitro killing assay in wt and PPARγKO macrophages. 
Primary bone marrow derived macrophages were infected with S.pneumoniae (10 bacteria: 1 macrophage) to 
determine intracellular killing in vitro. (f) 24 hour in vivo killing assay. Wt and PPARγlysM mice were infected 
intranasally with S.pneumoniae for 24hrs and percent bacterial survival was determined. (g) Phagosomal ROS 
production is lost in knockout macrophages. ROS was determined with FcOxyburst (Invitrogen). 
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killing assays. PparγKO macrophages also displayed similar rates of uptake and binding of 
bacteria compared to wt cells. PparγKO macrophages had 50% more surviving bacteria 
remaining in the macrophage compared to wt macrophages after 2 hours (Fig. 18e). Similar 
results were obtained in vivo when PparγLysM mice were infected intranasally with S.pneumoniae. 
24 hours post infection, PparγLysM mice had significantly more bacteria in the lungs compared to 
wt mice (Fig. 18f). These mice had similar numbers of cells within the lavage fluid. Differential 
cell counts of the Balf suggested increased neutrophil percentages, in accordance with increases 
in bacteria number (Supplementary Fig. 10a). Mechanistically, macrophages from knockout 
macrophages were also defective in Fc mediated ROS production (Fig. 18g). As expected from 
the single knockout phenotypes, mice with macrophage specific deletion of both Pparδ and Pparγ 
(PparδγLysM) are defective in both in vitro and in vivo bacterial killing (Supplementary Fig. 10b-
d). These mice are also unable to survive a bacterial challenge (Supplementary Fig. 10e). It is 
important to note that the double knockout mice display an increase in cell number in the Balf 
post infection, a phenotype not observed in either of the single knockout mice. Both Pparδ and 
Pparγ appear to display similar functional deficiencies, as all three types of mice exhibit similar 
defects in phagosomal ROS production. Taken together, it is clear that Pparγ plays a critical role 
in macrophage bacterial killing. 
Discussion 
 In Chapter 4, I investigated the role of lipid sensing nuclear receptors in bacterial killing. 
Here, I show that both Pparδ and Pparγ have a significant role in bacterial killing. I show that 
Pparδ regulates phagosomal ROS production and transcriptional activation of Noxo1. Lack of 
Pparδ in the macrophage contributes to inefficient bacterial killing. PparγLysM mice also exhibit 
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defects in bacterial killing in vitro and in vivo. The mechanism of action for Pparγ regulation of 
bacterial killing is unclear.  
Pparδ is a lipid sensing nuclear receptor. Despite its role in regulating metabolic 
processes in other cells, Pparδ does not appear to regulate these pathways during bacterial 
killing. As such, I have elucidated a mechanism by which Pparδ regulates phagosomal ROS 
production. The defects in ROS production lead to alterations in the ability of the macrophage to 
kill bacteria. This is observed in vitro and in vivo suggesting that there is a cell autonomous 
defect that contributes to the inability of macrophages lacking Pparδ to kill bacteria. I suggest 
here that the defect arises from an inability of Pparδ to regulate Noxo1 transcription. Noxo1 is a 
homologue of p47phox, an organizer protein that has been shown to associate with the Nox2 
complex to mediate proper phagosomal ROS production (Fig. 5). Phosphorylation of the AIR 
domain in response to pathogen ligation of surface receptors activates p47phox allowing for a 
tight regulation of ROS production in the phagosome156. Lack of the AIR domain in Noxo1 is 
thought to lead to constitutive activation and therefore contributes to the activity of the more 
ubiquitous oxidases, Nox1 and Nox3156,172. To date, a role for Noxo1 in phagosomal ROS 
production and bacterial killing has not been shown.  
Recently it was observed that Noxo1 is expressed in macrophages and that mRNA is 
induced in the presence of inflammatory agents such as LPS and Tnfα, suggesting that 
transcriptional upregulation of Noxo1 may play a role in the bactericidal activity of the 
macrophage171,262. Through in vitro assays, I show that Pparδ ligand, GW501516, is able to 
increase activity of the promoter of Noxo1. This effect was lost in cells that did not contain 
Pparδ. Analysis of the promoter of Noxo1 for PPAR binding elements revealed no sites that 
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match previously described patterns. One possible explanation is that Pparδ is activating a 
signaling cascade that converges on Noxo1 upregulation. However, the functional consequences 
of increases in Noxo1 transcriptional activation remain unclear. Several studies showed that 
Noxo1 can associate with Nox2 and p22phox263-265. Because these were done in vitro by 
overexpressing all of the proteins, it is arguable that the results are due to a forced association of 
the complexes. To address this question in vitro and in vivo, I am currently generating reagents 
that will allow for overexpression or knockdown Noxo1 in both wt and PparδKO macrophages. 
With these tools, I hope to link the role of Noxo1 to Pparδ regulation of phagosomal ROS 
production.  
Functional activation of Pparδ occurs when ligand binds to the ligand-binding domain of 
the protein and allows for association with promoter elements within target genes. My data show 
that stimulation of the macrophage with live or heat-killed bacteria can generate an endogenous 
ligand that activates Pparδ. It is possible that lipids on the surface of the bacterium could act as 
ligands, despite the fact that Pparδ is physically separated from the bacterium by at least the 
phagosomal membrane. It is unclear how bacteria are able to increase Pparδ activity and more 
work needs to be done to understand this regulation.  
In addition to the spatial disconnect between Pparδ and the bacterium, there is also a 
temporal disconnect. Activation of the macrophage occurs within seconds. The oxidative burst 
occurs within 15 minutes. Bacterial killing begins as early as 30 minutes after initiation of 
ingestion266. However, Pparδ, as a transcription factor, needs to be activated, initiate 
transcription and translation, and those proteins need to be used to effect a change. This process 
takes much longer than the time it takes to observe an oxidative burst or even to observe 
 
 
78 
bacterial killing. Rapid transcriptional activation has been observed as in the case of Nf-κb161, 
and a similar mechanism may be regulating rapid activation of Pparδ. Another explanation is that 
deficiencies in Pparδ manifest as defects in target proteins and lipids in the cell prior to bacterial 
infection. Pparδ could also be acting as a signaling molecule, instead of a transcription factor. 
Regardless of the mechanism, it is clear that Pparδ is able to affect phagosomal ROS production, 
either through an extremely rapid signal transduction cascade, a non-transcriptional mechanism, 
or prior deficiences in the cell. Further investigation will help to address this question.  
While the focus of this chapter was on Pparδ, I also presented data suggesting that Pparγ 
has a similar functional defect in bacterial killing. While PparγKO macrophages were also 
unable to increase phagosomal ROS production, this defect was not as significant as the defect in 
PparδKO macrophages. The data suggest that although redundant in function, Pparδ and Pparγ 
may regulate different pathways that regulate bacterial killing. Preliminary data from uninfected 
macrophages suggest that Pparδ may play a role in phagosomal regulation, while Pparγ appears 
to regulate the metabolic pathways that would generate ATP and NADPH. This data is supported 
by the fact that PparγKO macrophage exhibit defects in ATP and NADPH levels (Data not 
shown). Additionally, mice that are deficient in both receptors show similar phenotypes to both 
single knockout mice. However until a clear mechanism for Pparγ is determined, the interactions 
between Pparδ and Pparγ remain unclear.  
Using PparδγKO macrophages, I isolated phagosomes and identified several potential 
bands of interest whose expression was decreased in phagosomes from knockout compared to wt 
macrophages. These proteins could be mediating the defects observed in phagosomal ROS 
production. Using mass spectrophotometry, I can identify these bands in an unbiased manner 
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(Supplementary Fig. 11). Additionally, a comparison of phagosomal composition from 
PparδKO, PparγKO, and PparδγKO could help to identify pathways that are differentially 
regulated by the two receptors. Coomassie stain of the phagosomal proteins also showed reduced 
levels of protein in ATP pretreated phagosome samples from wt macrophages, as previously 
described in the literature267. This effect was lost in PparδγKO, suggesting that ATP availability 
may be influencing phagosome function (Supplementary Fig. 11).  
Neonates, elderly patients, and people with type 2 diabetes have increased rates of 
morbidity from bacterial and fungal infections compared to a young, healthy population, 
suggesting a common defect in immune function16,260,261,268. A previous study showed that mice 
with higher activity of nulear receptor co-repressors display decreased Pparδ activity and exhibit 
pathologies associated with aging. Polymorphisms in these same co-repressors are associated 
with type 2 diabetes and increased insulin resistance269. Age-associated changes in Ppar nuclear 
protein, mRNA levels, and promoter binding were also observed in rat kidneys251,270. I show that 
in alveolar macrophages from both young and old mice, expression of phagosomal genes is 
decreased. I also observe that in older mice, ROS production is decreased. Pparδ ligand can 
increase phagosomal ROS production in these mice. Ligand treatment is also able to improve 
bacterial killing and survival in eight-week-old mice. Together, I suggest a novel mechanism to 
increase host bacterial killing potential to improve killing efficiency. Further studies will 
determine if ligand treatment post infection can recapitulate these same findings. Additionally, 
studies should be conducted addressing the ability of combination treatments involving Pparδ 
ligands and antibiotics in the treatment of bacterial infections. While Pparδ ligand appears to 
improve bacterial killing, it is also likely that use of multiple ligands to improve several 
pathways of host killing could be much more potent. If these pathways regulate bacterial killing 
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in the human macrophage, it would also be exciting to see if similar ligands could be used to 
treat other types of bacterial, viral, or fungal stresses. In recent years, a lack of novel antibiotics 
and the rise of multi-drug resistant pathogens have led to the immediate need for novel 
therapeutics (CDC, WHO). The link between Pparδ and phagosomal function provides a novel 
mechanism to improve bacterial killing.   
 
Material and Methods 
All methods are the same as in Chapter 2 and 3. Additional methods utilized in Chapter 4 are 
detailed below. 
Bacterial growth and manipulation. Streptococcus pneumoniae, serotype 3 was obtained from 
American Type Culture Collection. Bacteria were cultured as described previously 271. For large 
volumes of S.pneumoniae, bacteria was cultured in Tryptic Soy Broth for 8 hours at 37oC 
without shaking. Fluorescent magnetic beads (BM570, Bangs Laboratory) were conjugated to 
S.pneumoniae as previously described272. S.pneumoniae was heat-killed by incubation at 50oC 
for 40mins.  
 
Animal experiments. Pparδ and Pparγ floxed animals were generated as described 
previously273,274. Pparδ and Pparγ mice were crossed to lysozyme cre mice (Jackson laboratory) 
to generate PparδLysM, PparγLysM, and PparδγLysM mice. Pparδfl/fl, Pparγfl/fl, and Pparδγfl/fl mice 
were used as wt controls. All mice were maintained on a C57BL/6 background. For in vivo 
killing assays, mice were anesthetized with a ketamine/xylazine solution and infected 
intranasally with 106 CFU S.pneumoniae. 24 hours post infection, mice were sacrificed with 
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isofluorane and Balf was extracted271. For survival experiments, mice were infected intranasally 
with 105 CFU S.pneumoniae. Mice were observed for signs of distress twice a day for 2 
weeks271. Ligand was gavaged for the indicated amount of time at a dose of 2mg kg-1 per day. 
All animal studies were approved by the Harvard Medical Area Standing Committee on 
Animals. 
 
Primary cells and stable cell lines.  Bone marrow derived macrophages were differentiated as 
described previously and in chapter 2. Stables lines were created from bone marrow of all the 
different knockout and control mouse lines using a CreJ2 viral system275,276. A retroviral Cre 
virus was then used to generate clonal wt and knockout cell lines. Retroviral vectors were also 
used to generate cell lines overexpressing Pparδ or Pparγ. Alveolar macrophages were obtained 
from mice by lavage after sacrifice.  
 
Functional assays. Gentamicin protection assays were used for in vitro bacterial killing277,278. 
Briefly, macrophages were incubated with S.pneumoniae. After 1 hour, cells were washed and 
gentamicin (200µg/ml) was used to kill extracellular bacteria. Cells were allowed to proceed 
with killing for an additional hour. Colony forming units (CFU) were determined as a measure of 
bacterial survival. ROS assays were done using FcOxyburst according to manufacturers 
protocols using either FACS or a 96-well luminometer (Invitrogen). pH was determined with 
E.coli labelled pHRODO (Invitrogen). ATP and lactate were measured using commercially 
available kits. Phagocytosis and phagosome number were determined FACS using Alexa Fluor 
647 labeled heat killed S.pneumoniae279. Phagosomal pH was measured by FACS using heat 
killed S.pneumoniae that was doubly labeled with Alexa Fluor 647 and FITC279. Phagosomes 
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were isolated as previously described280. Briefly, macrophages were incubated with magnetic 
beads and allowed to phagocytose. Post infection, cells were collected and samples were 
homogenized manually. Beads were isolated from supernatants and analyzed by Western blot. 
Equal fluorescence was loaded. Mitotracker (Invitrogen) was used to determine mitochondrial 
number. Glucose uptake was determined as previously described.  
 
Immunoblotting experiments. I performed Western blot analyses using the following 
antibodies: v-ATPase D2 (Santa Cruz # sc-69111, Clone S-20, 1:500); gp91phox (Nox2, Santa 
Cruz # sc-5827, Clone C-15, 1:500); Lamp1 (Santa Cruz # sc-19992, Clone 1D4B, 1:1000); 
Actin (Cell Signaling #4970, Clone 13E5, 1:1000). 
 
Statistical analyses. Statistical analyses comparing two parameters (between treatments or 
genotypes) in cell-based work were conducted using the two-tailed Student’s t test. Two 
parameters analyses for samples from in vivo studies (non-gaussian distribution) were 
determined using the Mann-Whitney test (Figs. 14b-c, 15a,b,d,e, 16c-d, f and Supplementary 
Figs. 9a-d, 10a, 10c-d). Statistics for multi-parameter analyses was determined by One-Way 
ANOVA followed by Bonferroni posthoc tests (Figs. 13c-e, 5c, 6a, 6d). Two-way ANOVA was 
used to determine statistical significance for GTT and ITT (Figs. 14a, 15f,). Kaplan-Meier 
statistics were used for the survival curves (Fig. 15c and Supplementary Fig. 10e). Values are 
presented as mean ± s.e.m. For in vitro assays, the mean and s.e.m. were determined from 3–4 
biological replicates for one representative experiment. Experiments were repeated at least three 
times. P<0.05 was considered significant.  
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Summary and Significance 
A critical balance exists between immune and metabolic pathways within the host. In the 
course of aging or in states of gluttony and energy storage, this homeostasis becomes 
dysregulated leading to a plethora of diseases characterized by chronic inflammation, poor 
immune responses, and metabolic stress. With improved hygiene and access to better healthcare, 
the world population is rapidly aging249. Associated with this increase in an elderly population is 
an increase in the incidence of cancer, the metabolic syndrome, and infectious diseases249. 
Efforts to identify effective therapies for treatment of associated pathologies are paramount 
(ADA, WHO). Understanding the homeostatic balance between immune systems, metabolic 
systems, and non-self pathogens can help to inform the development of immuno-metabolic 
therapeutics to treat immunological and metabolic diseases.  
In this thesis, I addressed three previously uncharacterized interactions that can help to 
deal with the growing burdens of metabolic and infectious diseases. In chapter 2, I showed that 
immune modulation by pathogenic products can alter metabolic function. Here, I demonstrate the 
utility of LNFPIII as an immunomodulatory therapeutic. In chapter 3, I describe a previously 
unidentified observation that helminth derived glycans can modulate hepatic lipogenic function. 
The role of this appears to be evolutionary and provides a novel mechanism to treat fatty liver 
diseases. This observation also suggests that agonists or antagonists of host metabolic pathways 
can be used treat infectious diseases. In this example, use of Fxr modulators could be developed 
as a novel treatment for schistosomiasis. This notion of altering metabolic pathways to treat 
infectious diseases serves as the foundation of the work described in chapter 4. My data suggest 
that phagosomal ROS production is dependent on Pparδ activity. In old mice or in genetic 
deletion of Pparδ, where Pparδ activity is low or nonexistant, macrophages have decreased 
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phagosomal ROS production, leading to increased bacterial burden. Increasing Pparδ activity 
through ligand activation proved to be a potential mechanism to improve bacterial killing in 
susceptible murine populations. Together, the data in these three chapters support the concept 
that altering metabolic pathways can be critical in treating infectious diseases. The data also 
show that altering immune states can directly influence metabolic outcomes. However, these 
studies are only the beginning of an exciting area of research that has potential for application to 
many different organ systems, immune platforms, and infectious agents. By understanding these 
interactions, we can work to develop novel therapeutics that can influence both metabolic and 
immunological dysfunctions. Below are areas of research that should be addressed to improve 
the understanding of these critical pathways. 
 
Current state of research: Role of inflammation in metabolic dysregulation 
 Macrophages have evolved to sense dietary fats. The role of cholesterol in macrophage 
pro-inflammatory responses and atherosclerosis is well established42,281. Recent studies have 
further demonstrated that fatty acids have a broad spectrum of activities on macrophage 
activation. This is particularly relevant in obesity, in which the interaction of adipocytes and 
macrophages through fatty acid dependent mechanisms is critical to metabolic homeostasis (Fig. 
3). Dietary ω-3 fatty acids and their derivatives, including EPA, DHA and resolvins, can inhibit 
inflammatory responses through GPCRs or PPARs145,146 and as such, represent an attractive 
means for dietary intervention to reduce metabolic inflammation. In addition to dietary fats, 
studies have suggested that some amino acids, such as arginine and glutamine, promote insulin 
sensitivity and insulin secretion282-284. However, epidemiological data also suggests that levels of 
branched chain amino acids are associated with diabetes as early as 12 years before onset of frank 
 
 
87 
insulin resistance285,286. The role of amino acid sensing pathways in macrophage function and 
metabolic inflammation is controversial. In cultured macrophages, glutamine and arginine are 
critical for cytokine secretion, eicosanoid production and phagocytic uptake during macrophage 
activation287. Mammalian target of rapamycin (mTOR), a major amino acid sensing molecule, is 
anti-inflammatory in the macrophage. However, mTOR inhibition by rapamycin blocks MCP1 
production, despite its pro-inflammatory phenotype288. Additional work is needed to clarify the 
roles of amino acids in metabolic syndrome and infectious diseases and whether these effects are 
mediated, in part, through macrophage activation.  
While it is evident that metabolic stress (e.g., fatty acids, ceramides and ox-
LDL/cholesterol) induces macrophage inflammation, the detailed mechanisms through which 
pro-inflammatory signaling pathways cause metabolic diseases, notably in the setting of insulin 
resistance, remain unclear. For example, contradictory results have challenged the role of myeloid 
Jnk1 in insulin resistance289,290. It appears that the initiation of a chronic inflammatory cycle may 
be due to loss of anti-inflammatory and/or regulatory signaling. However, the beneficial effects 
associated with alternative activation also require further investigation, as TH2 cytokines are 
known to mediate allergic responses. Recent reports have implicated several other immune cell 
types, such as T lymphocytes, mast cells, natural killer cells and eosinophils, in modulation of 
insulin sensitivity126,186-188,291-293. For example, T cell deficient Rag–/– mice are more susceptible 
to diet induced obesity and adoptive transfer of Cd4+Foxp3+ T regulatory cells restores energy 
balance in these mice186,188,294. These studies indicate that the interactions between the innate and 
adaptive immune systems also contribute to the onset of the metabolic syndrome and implicate an 
auto-immune response in the associated pathologies. What have not been described are the 
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temporal recruitment and activation of various immune cells in metabolic tissues and the role of 
their interaction in metabolic diseases.  
Other anti-inflammatory or immunomodulatory mechanisms may be relevant in 
maintaining metabolic homeostasis. Certain miRNAs are up-regulated by TLR signaling and act 
through Nf-κb pathways to dampen the inflammatory response295,296. miRNAs have also been 
implicated in atherosclerotic plaque initiation and expansion297. In addition, gut flora has been 
shown to modulate energy utilization efficiency and adiposity and contribute to the onset of 
metabolic diseases 298,299. Helminth infection is known to deactivate the immune response and 
mice infected with parasitic worms exhibit improved insulin sensitivity, suggesting potential use 
of helminthic antigens for therapies. Lastly, exercise reduces blood inflammatory markers and 
improves metabolic parameters. The so-called myokines produced by muscle after physical 
activity may modulate macrophage activation300-303. In fact, exercise induced improvements in the 
inflammatory profile were found to be independent of weight loss304,305. Through understanding 
these different aspects of metabolic-related immune responses, it may be possible to design drugs 
to specifically target the feed-forward loop of metabolic stress-induced inflammation without 
unwanted side effects, such as immuno-suppression or allergic responses.  
 
Immunomodulation as a therapeutic for chronic inflammation  
An attractive method to treat chronic inflammatory pathways is through 
immunomodulation. However, immunomodulatory therapeutics must be developed cautiously 
because of a limited understanding in the intricate relationship between metabolic tissues (e.g., 
muscle, liver, and WAT) and immune cells. Use of TH2 cytokines such as Il-4 and Il-13 prove 
problematic due to their role in onset of allergies. It is also important to avoid therapeutics that 
 
 
89 
would suppress the immune system, thereby compromising host defenses. Salicylates, inhibitors 
of the Nf-κb inflammatory response, have also shown promise in improving glycemic parameters 
in non-diabetic obsese adults, although immuno-suppressive side-effects have not been 
addressed306.  
The human host and several parasites co-evolved, with evidence suggesting that parasites 
developed glycans to mimick host mechanisms of immune suppression in an effort to live 
symbiotically for decades with the host199. In fact, many of the glycans used by parasites to 
maintain symbiotic relationships are found in human breast milk and other sources202. 
Epidemiological data suggest that children who are breast-fed are less likely to develop allergies, 
auto-immune diseases, and metabolic syndrome307-309. This implicates loss of glycan-derived 
immunomodulation in the development of auto-immune and inflammatory diseases. It also 
suggests an evolutionary mechanism to modulate the immune system and suppress inflammatory 
signaling. While the data in chapter 2 suggests that LNFPIII can be a promising therapeutic for 
chronic inflammatory diseases, more research is needed to elucidate the long term effects of 
glycan treatment and the most efficacious age for treatment.  
When treating HFD-insulin resistant mice with LNFPIII, I observe a small, yet insignificant 
increase in body weight that is associated with a significant increase in WAT mass. This increase 
in weight is most likely due to the ability of insulin sensitive adipose tissue to store more lipids. 
This phenotype is observed in other therapeutics that improve WAT insulin sensitivity, such as 
Pparγ agonists and sulfonylureas310,311. It is unclear if long term treatment with LNFPIII will 
significantly influence body weight or lead to other unwanted side effects. I also observe 
recurrence of insulin resistance after glycan withdrawl (Data not shown). However, young 
children who are exposed by breast-feeding to these same glycans prior to the formation of their 
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adult immune systems appear to sustain the beneficial effects of immunomodulation. This would 
suggest that the glycans provide a type of “memory” to innate immune cells. Additional work 
understanding the temporal regulation of LNFPIII immunomodulation can help to understand the 
role of pathogen interactions in the formation of a strong immune system.  
 
Current state of research: Role of metabolic pathways in immune dysfunction 
The incidence of the metabolic syndrome and susceptibility to infections increases with 
age312. Age has also been associated with a decline in immunological function313,314. What 
remains unclear is whether the decline in immunological function is due to a loss of metabolic 
regulation in immune cells. At a systemic level, older patients have a slowed metabolic rate and 
display signs of metabolic dysregulation315. My research suggests that metabolic dysregulation in 
the macrophage, through fatty acid sensing receptor deletion, has adverse affects on bacterial 
infection.  
The role of metabolic pathways in macrophage function has been shown previously. Rate 
of de novo lipogenesis is increased in the macrophage upon stimulation by a pathogen. Srebp1a, 
a receptor from the sterol regulatory binding protein family of receptors known to regulate lipid 
and cholesterol metabolism, is very highly expressed in the macrophage and Nf-κb has been 
shown to bind to an element in the promoter to induce transcription during bacterial 
stimulation169. In fact, lack of Srebp1a protects mice from infection with Salmonella 
typhimurium, although this effect was proposed to be due to suppression of a heightened 
cytokine storm169. Flux of glucose through the pentose phosphate pathway (PPP) is also 
increased during bacterial stimulation159. Decreased glucose-6-phosphate dehydrogenase 
(G6pdh) activity is associated with decreased NADPH oxidase activity in neutrophils316. Studies 
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looking at the role of other metabolic regulators, such as liver x receptor, farnesoid x receptor, 
mammalian target of rapamycin (mTor), and insulin receptor, suggest that many receptors in the 
macrophage sense metabolic status and affect macrophage function by altering cellular functions, 
the most commonly described being cytokine production42,140,317-320.  
 
Metabolic modulators in the treatment of infections 
The critical relationship between metabolic pathways and immune cell functions, 
suggests that development of therapeutics modulating metabolic pathways can be used to treat 
infectious diseases. In chapter 4, I show that Ppar agonists can improve bacterial killing and 
survival in eight-week-old mice. Here, I suggest a novel mechanism to increase host bacterial 
killing potential to improve killing by modulating metabolic pathways. Further studies will 
determine if ligand treatment post infection can recapitulate these findings. Additionally, studies 
should be conducted addressing the ability of combination treatments involving Pparδ ligands 
and antibiotics. While Pparδ ligand appears to improve bacterial killing, it is possible that use of 
multiple ligands to improve several pathways of host killing could be much more potent.  
Lastly, the translation of these studies to humans should be addressed. An important 
concern is that metabolic pathways are regulated differently in murine and human macrophages. 
For example. PPARα, a third isoform of the PPAR family of receptors, has more of a 
contribution to macrophage function in humans than in mice140. In the murine macrophage, 
Pparα expression is much lower than Pparδ or Pparγ and the contribution of Pparα to murine 
macrophage function is limited140. In the human and murine macrophage, PPARα ligand was 
shown to increase NADPH oxidase function and ROS production321. If these pathways regulate 
bacterial killing in the human macrophage, it would also be exciting to see if similar ligands 
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could be used to treat other types of bacterial, viral, or fungal stresses. In recent years, a lack of 
novel antibiotics and the rise of multi-drug resistant pathogens have led to the immediate need 
for novel therapeutics (CDC, WHO). Through understanding these different aspects of 
metabolic-related immune responses, it may be possible to design drugs to specifically improve 
metabolite-regulate immune function and outcomes of infectious responses.  
 
Concluding thoughts 
 In this thesis I have shown that metabolic pathways can be manipulated to treat infectious 
diseases. I have also shown that proper functioning of immune pathways contributes to metabolic 
homeostasis. Further investigation into these pathways will help to understand the roles that 
metabolic, immune, and pathogenic signaling play in maintaining physiological homeostasis in 
an effort to prevent pathological dysregulation.  
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Supplementary Figure 1 Induction of Il-10 by LNFPIII is independent of TH2 cytokines. (a) LNFPIII induces Il-10 
and Arg1 expression in a dose-dependent manner. Bone marrow derived macrophages were treated overnight with 
10, 20 or 40 ng mL–1 of Il-4 or 10, 20 or 40 µg mL–1 of LNFPIII. Gene expression was determined by RT q-PCR. 
(b) Regulation of Il-10 expression (left panel) and production (right panel) by LNFPIII (20 µg mL–1) in dendritic 
cells (c) LNFPIII induced Il-10 expression is independent of Pparδ and Stat6. Wild type (wt), Ppard–/– and Stat6–/– 
macrophages were given 20 µg mL–1 LNFPIII overnight. (d) SEA treatment increases levels of circulating Il-10 and 
Il-4 in vivo. Serum Il-10 and Il-4 concentrations were measured in vehicle or SEA treated mice (n=4–6/treatment) 
used for metabolic studies. (e and f) Improved glucose tolerance (GTT, e) and insulin sensitivity (ITT, f) in mice 
treated with SEA. Male C57BL/6J mice (n=4–6) fed a high fat diet for 6 weeks were given vehicle or SEA (25 
µg/twice a week). GTT and ITT were conducted at 4th and 5th weeks, respectively, after treatment. Inset: area under 
the curve (AUC). (g) SEA treatment decreases fasting insulin levels and increases systemic insulin sensitivity 
determined by HOMA-IR. Values are expressed as means ± s.e.m.. For in vitro assays, the mean and s.e.m. were 
determined from 3–4 biological replicates for a representative experiment. Experiments were repeated three times. 
In vivo studies were reproduced in three mouse cohorts (n=4–6/treatment). *P<0.05 (SEA versus vehicle control). 
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Supplementary Figure 2 SEA reduces inflammation and enhances metabolic homeostasis in WAT. (a) Histological 
analysis showing less crown-like structures in SEA treated WAT. Arrows indicate crown-like structures. Scale 
bar=100 µm. (b) Increased M2 and decreased M1 gene expression in SEA treated mice, compared to vehicle treated 
controls (n=5/treatment). (c) Metabolic gene expression in WAT from vehicle or SEA treated mice. WAT was 
collected at the end of metabolic studies. Gene expression was determined by real-time q-PCR. Values are expressed 
as means ± s.e.m. Metabolic studies were reproduced in three mouse cohorts (n=4–6/treatment). Crown-like 
structures and expression analyses were examined in one and two of the three cohorts, respectively. *P<0.05 (SEA 
versus vehicle control). 
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Supplementary Figure 3 The insulin sensitizing activity of LNFPIII/SEA is mediated by Il-10. (a and b) The effect 
of LNFPIII on inflammatory and metabolic gene expression in WAT is abrogated in Il10–/– mice (n=6/treatment). 
Mice were injected intraperitoneally with vehicle of LNFPIII for 6 weeks following 6 weeks on high fat diet. (c) The 
insulin sensitizing effect of SEA is lost in Il10–/– mice. Left and middle panels: ITT in wt and Il10–/– mice 
(n=6/treatment) treated with vehicle or SEA. Right panel: area under the curve of ITT. (d) GTT and (e) ITT showing 
rIl-10 treatment improves glucose tolerance and insulin sensitivity. Male C57BL/6J mice (n=5) fed a HFD for 4 
weeks were given three treatments of PBS (vehicle) or rIl-10 (1 ug/every other day). (f) rIl-10 treatment increases 
serum Il-10, but not Il-4 levels. (g) WAT exhibits reduced inflammatory and increased M2 gene expression 
following rIl-10 treatment. (h) rIl-10 increases expression of insulin signaling and lipogenic genes in WAT. Values 
are expressed as means ± s.e.m. Studies using Il10–/– and control mice (n=6/treatment/genotype) and in rIl-10 
treatment (n=6) were conducted in 1 cohort. *P<0.05 (treatment versus vehicle control); #P<0.05 (Il10–/– versus wt). 
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Supplementary Figure 4 SEA protects against hepatic steatosis and suppresses lipogenic gene expression.  (a) 
Representative liver histology images from vehicle or SEA treated mice (n=5). Scale bar= 100 µm. Right panel: 
hepatic triglyceride content. (b) SEA improves overall liver function as assessed by circulating AST and ALT 
levels. (c and d) Expression analyses of metabolic genes and nuclear receptor signaling pathways known to regulate 
lipogenesis in livers from vehicle or SEA treated mice (n=5) by real-time q-PCR. (e) Gene expression in muscle 
from vehicle or SEA treated mice determined by real-time q-PCR. Values are expressed as means ± s.e.m. 
Metabolic studies were reproduced in 3 mouse cohorts (n=4–6/treatment). Histology was examined in one and lipid 
and expression analyses were examined in two of the three cohorts. *P<0.05 (SEA versus vehicle control).  
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Supplementary Figure 5 LNFPIII, but not Il-10, suppresses de novo lipogenesis in the liver. (a) LNFPIII has a 
direct effect on lipid metabolism ex vivo in primary hepatocytes. Hepatocytes were treated with vehicle, LNFPIII 
(20 µg ml–1) or Il-10 (10 ng ml–1) for 24 hr. Cells were washed and subjected to lipogenesis assays. (b and c) rIl-10 
treatment (n=5/treatment) does not affect the triglyceride content or lipogenic gene expression in the liver. (d and e) 
LNFPIII treatment in Il10–/– mice (n=6) reduces hepatic triglyceride content and suppresses lipogenic gene 
expression. (f) Gene expression analyses in livers from Fxra–/– mice treated with vehicle or LNFPIII (n=6) by real-
time q-PCR. (g) ITT in Fxra–/– mice (n=6) treated with SEA. (h) LNFPIII treatment improves insulin sensitivity 
determined by ITT in Fxra–/– mice (n=6). (i) Ex vivo insulin stimulated glucose uptake in adipose tissue slices. 
Adipose tissue slices were collected before and after portal vein injection of 5U kg–1 insulin and immediately 
subjected to glucose uptake assays. Values are expressed as means ± s.e.m. For in vitro assays, the mean and s.e.m. 
were determined from 3–4 biological replicates for a representative experiment. Experiments were repeated three 
times. Studies using rIl-10 (n=6), Il10–/– (n=6), Fxra–/– (n=6) and corresponding controls were performed in 1 mouse 
cohort. *P<0.05 (treatment versus control).  
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Supplementary Figure 6 (a) Sequence comparison of the 5’ proximal regulatory region of human, rat and mouse 
Fxrα downstream promoter (promoter 2). The transcriptional start site is indicated with an arrow. Putative binding 
sites for C/EBP (site 1) and AP1 (site 2 and site 3) are highlighted. Sequences mutated for the reporter assays are 
indicated above the highlighted binding sites. (b) Reporter assays showing that the induction of Fxrα promoter 2 is 
mediated by AP1 binding sequences in site 3. Mutations in sites 1 and 2 had no effect. Similar results were obtained 
with LNFPIII treatment (data not shown). (c) LNFPIII (20 µg ml–1) or SEA (2 µg ml–1) modulate hepatic lipid 
metabolism in an Fxrα-dependent manner. Functional assays were conducted in hepatocytes isolated from wild type 
(wt) or Fxra–/– mice 24 hr after treatments. (d) Inhibition of Erk activation blocks the activity of SEA in suppressing 
lipogenesis in hepatocytes. Left panel: Western blot analyses showing that PD98059 inhibits Erk phosphorylation 
(p-Erk). Cells were pretreated with PD98059 for 1 hr prior to overnight SEA treatment. p-Erk: phospho-Erk; t-Erk: 
total Erk. Actin was included as a loading control. Right panel: in vitro de novo lipogenesis assays in hepatocytes. 
Values are expressed as means ± s.e.m. Mean and s.e.m. were determined from 3–4 biological replicates for a 
representative experiment. Experiments were repeated three times. *P<0.05 (SEA/LNFPIII versus vehicle control). 
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Supplementary Figure 7: Pparδ expression is increased in macrophages during infection with S.pneumoniae. (a) 
Expression of Pparδ and its target gene Slc25a20 was determined by RT qPCR in macrophages infected with 
S.pneumoniae for the indicated time.  
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Supplementary Figure 8: PparδKO macrophages do not have defects in mitochondrial number, lactate production, 
and ATP generation in vitro. (a) Gene expression of metabolic enzymes in wt and PparδKO macrophages. (b) 
PparδKO macrophages have decreased glucose uptake. Cells were incubated with insulin followed by incubation 
with 2-[H3]deoxy-D-glucose. (c) PparδKO macrophages have an equal number of mitochondria compared to wt 
macrophages. Mitochondrial number was determined by normalizing a mitochondrial gene (ND1) and a nuclear 
gene (36B4). Mitochondria were also quantified by mitotracker staining and fluorescence quantification (d) Pparδ 
knockout macrophages infected with E.coli do not have a defect in lactate production.  (e) ATP production by wt or 
PparδKO macrophages during infection is equal.  
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Supplementary Figure 9: Complete cell counts in wt and PparδLysM mice show no defects in recruitment. (a) 
Complete blood counts from blood of infected mice. (b) Total number of cells obtained from wt and PparδLysM mice 
after 24 of infection. Mice were intranasally with S.pneumoniae and cells were counted 24 hours post infection. (c) 
Differential cell counts were determined on bronchoalveolar lavage fluid (Balf) from infected mice. (d) Cytokines 
were measured in Balf 24 hours post infection.   
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Supplementary Figure 10: PparδγLysM mice have a defect in bacterial killing. (a) Total cell number was determined 
from lavage fluid of PparγLysM mice infected intranasally with S.pneumoniae for 24 hours. Macrophages, neutrophils, 
and lymphocyte cell counts were determined in alveolar lavage fluid from mice infected with S.pneumonia for 24 
hours. (b) In vitro killing assay in wt and PparδγKO macrophages. Primary bone marrow derived macrophages were 
infected with S.pneumonia (10 bacteria: 1 macrophage) to determine intracellular killing in vitro. (c) 24 hour in vivo 
killing assay. wt and PparγlysM mice were infected intranasally with S.pneumoniae for 24hrs and percent bacterial 
survival was determined. (d) Total cell number was determined from lavage fluid of PparγLysM mice infected 
intranasally with S.pneumoniae for 24 hours. Macrophages, neutrophils, and lymphocyte cell counts were 
determined in alveolar lavage fluid. (e) Survival of wt or PparδγLysM mice. Mice were infected with bacteria and 
survival was followed for 2 weeks.  
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Supplementary Figure 11: Phagosome isolation from wt and PparδγLysm mice. (a) Macrophages were infected with 
magnetic beads and phagosomes were isolated after homogenization. ATP was used to disrupt binding of actin and 
other scaffolding proteins. Stars mark bands of potential interest.  
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